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What Cancer Cannot Do 
 
Cancer is so limited... 
 
It cannot cripple love 
 
It cannot shatter hope 
 
It cannot corrode faith 
 
It cannot destroy peace 
 
It cannot kill friendship 
 
It cannot suppress memories 
 
It cannot silence courage 
 
It cannot invade the soul 
 
It cannot steal eternal life 
 
It cannot conquer the spirit 
 










“Love is the bridge between you and everything.” 
 




POPULAR SCIENCE SUMMARY OF THE THESIS 
Pancreatic cancer is a disease in which malignant (cancer) cells develop and grow 
unrestrained by usual control mechanisms in the pancreas, an organ located in the abdomen 
behind the lower part of the stomach. As the tumor grows, cancer cells invade neighboring 
tissues and organs, such as the distal bile duct, a tubular structure that crosses the pancreas to 
allow a fluid called bile to drain from the liver into the small intestine. In addition, pancreatic 
cancer cells tend to grow into vessels and nerves and travel along them to other tissues and 
organs, even distant ones, like the liver or the lungs. Once pancreatic cancer cells reach these 
distant organs, they form new cancer growths, called metastases, that progressively occupy 
and destroy these organs, causing considerable, and ultimately fatal, worsening of patient’s 
condition. 
Once pancreatic cancer is detected, there are various possible treatments, but unfortunately, to 
date they are not effective enough to eliminate all cancer cells and cure the patient. The most 
effective treatment is to remove the tumor by surgical operation, following which - after a 
few weeks of recovery – the patient is treated with anti-cancer drugs (so-called 
chemotherapy). Chemotherapy kills and damages a part of the cancer cells and slows down 
the disease, but after months of treatment, the cancer cells change to become unaffected by 
the chemotherapy and resume their uncontrolled growth. 
There is an urgent need to develop new, more effective treatments for pancreatic cancer, like 
what has been achieved for other cancer types, such as breast and bowel cancer. These were 
also often fatal some years ago, but now there are treatments that are very effective to slow 
down and even cure the disease. 
The work in this thesis aims at contributing to the current efforts in the medical and scientific 
community to develop better treatment for patients with pancreatic cancer. This endeavor was 
undertaken in three ways:  
First, by showing that not all pancreatic cancers are identical when it comes to their 
microscopic appearance and aggressiveness, by investigating whether this could be the basis 
for distinguishing between different subtypes. For example, in some pancreatic cancers the 
tumor cells resemble those from bowel cancer, they usually grow more slowly, and patient 
survival is longer. Discrimination between distinct cancer subtypes can be done more 
precisely by using a special technique that stains the cells depending on the presence of some 
special components, called proteins, that appear in certain but not in other cancer subtypes. 
Second, by establishing a new method that allows to test in the laboratory which anti-cancer 
drugs may be more effective to kill an individual patient’s cancer cells. This is currently done 
by testing different drugs on either commercially available isolated cancer cells or animals 
(usually mice) with pancreatic cancer. But even if results are promising in these experiments, 
the same drugs often have a disappointing effect when given to humans, likely because both 
the cancer cells and the surrounding tissues are very different in patients than they are in the 
experiments. With the new technique, a small piece (up to 1 cm in size) of tissue is taken 
from the patient’s pancreatic cancer which has been removed by the surgeon, and this tissue 
is cut into very thin slices (one third of mm thick). We could show that these pancreatic 
 
 
cancer slices can be maintained intact and alive in the laboratory for at least 4 days. This 
gives us the possibility to search (in the laboratory) for effective anti-cancer drugs by testing 
them in the tumor slices, in which the cancer cells and surrounding tissues are very similar to 
those in the patient. Therefore, drugs that show good effect when using this new method, are 
likely to be also effective when tested in patients.  
Third, we tested the efficacy of selenium, a nutrient that is essential for human health, as an 
anti-cancer drug in the thin slices of pancreatic cancer as described above. Remarkably, most 
pancreatic cancer cells were killed after treating them with selenium, while the neighboring 
(normal) cells remained alive. That is, selenium was effective specifically against pancreatic 
cancer and this effect occurred at doses that can safely be administered to patients without 
causing serious toxic side effects. 
In summary, the work laid down in this thesis, that is the distinction between pancreatic 
cancer subtypes of different aggressiveness, the new laboratory model based on tumor slices 
to test for effective drugs, and the demonstration of promising anti-cancer effects of selenium, 
will contribute to the development of more effective treatment that is better suited for the 









Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer, is 
associated with a dismal 5-year overall survival of 9 to 6 %. A major reason for the high 
mortality is the pronounced resistance to treatment. There is urgent need for the development 
of novel, effective therapies and for a better understanding as to why some tumors respond 
better to treatment than others. 
The process for conventional drug testing relies significantly on cell lines and genetically 
engineered mouse models. Even if these models recapitulate some of the features of human 
pancreatic cancer, there are significant limitations, mainly the lack of the native tumor 
microenvironment and the use of a host that belongs to another species and may be 
immunocompromised. 
In Paper I, a large cohort (n = 409) of adenocarcinomas from the main anatomical locations 
in the pancreatobiliary system is analyzed by immunohistochemistry with a panel of up to 27 
antibodies. Hierarchical clustering and differential expression analysis reveal three 
immunohistochemical tumor types (extrahepatic pancreatobiliary, intestinal and intrahepatic 
cholangiocarcinoma) and their distinguishing markers. Among patients who underwent 
surgical resection of the primary tumor, the intestinal type showed an adjusted hazard ratio of 
0.19 for overall survival (p value = 0.014) as compared to the extrahepatic pancreatobiliary 
type. Furthermore, the characteristic immunohistochemical profile supports the positive 
diagnosis of intrahepatic cholangiocarcinoma, which is commonly regarded as a diagnosis of 
exclusion. The presented integrative immunohistochemical classification may contribute to 
improve diagnosis and prognostic stratification for patients with adenocarcinomas of the 
pancreatobiliary system. 
Paper II introduces a novel ex-vivo model of precision-cut tissue slices that allows culturing 
of human PDAC including the native tumor microenvironment. Fresh tumor tissue samples 
(n = 12) were obtained from surgical resection specimens, cut into 350 μm thick tissue slices, 
and cultured for at least 96 h. Every 24 h, tissue slices were harvested and processed for 
analysis, including histomorphology, transmission electron microscopy and 
immunohistochemistry. These revealed good morphological preservation and ultrastructural 
integrity of the tissue slices, including cancerous, stromal, and immune cell populations. Each 
tumor retained its characteristic histological and cytological features and grade of 
differentiation throughout the entire culture period. A cancerous and, to a lesser extent, non-
neoplastic cell outgrowth covered gradually the surface of the tissue slices, while tumor cells 
retained their proliferative (Ki67) and metabolic (pS6 mTOR pathway) activity. This culture 
system is a close surrogate of the parent tumor and harbors promising potential for drug 
sensitivity testing and personalized treatment of PDAC. 
Paper III is a continuation study in which five tissue slice cultures of human PDAC (from 
Paper II) are analyzed at the whole transcriptome level (RNASeq). Findings at 24 h intervals 
(24-72 h of culture) are compared to baseline (0 h, non-cultured tissue). On differential 
expression analysis, only a limited number of genes (median range 10-25) were up- or 
downregulated during culture. One culture with morphologically visible regions of 
necrosis/apoptosis (0-18 % total slice area) showed upregulation of VEGFA and PTGS2. 
 
 
Pathway analysis suggested for this culture a highly significant probability of activation of 
apoptosis via HIF-1/quercetin/NF-ĸB/AP-1 interaction pathways. These results support that 
the transcriptome of the parent tumor is largely preserved in ex-vivo cultured tissue slices of 
PDAC, and that transcriptomic analysis is a valuable complement to morphology for 
evaluation of the tissue slices. 
Finally, in Paper IV, the previously established (in Papers II and III) ex-vivo model of 
precision-cut tissue slices is used for drug sensitivity testing in nine samples of surgically 
resected human PDAC. PDAC tissue slices were exposed to selenium compounds (selenite 
and methylselenocysteine) at various concentrations and gemcitabine 1 μM during 48 h of 
culture. Selenium compounds administered at concentrations below the maximum tolerated 
dose in humans significantly reduced PDAC cell viability (p < 0.02) and decreased outgrowth 
of viable tumor cells onto the tissue surface (p < 0.05), while non-neoplastic tissues remained 
preserved. Transcriptomic analysis revealed downregulation of CEMIP, PLOD2, DDR2 and 
P4HA1, genes that are involved in extracellular matrix modulation, cancer growth and 
metastatic potential, while the cell death-inducing genes ATF3 and ACHE were significantly 
upregulated (p < 0.0001).  
In conclusion, the results of this thesis support the value of immunohistochemical profiling 
for the diagnosis of prognostically significant subtypes of periampullary adenocarcinomas. 
The findings confirm the relevance of the precision-cut tissue slice culture model for 
anticancer drug sensitivity testing and the potential of selenium compounds as candidate 
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1.1 THE PANCREAS 
The pancreas is an elongated organ located retroperitoneally to the left in the posterior 
abdominal cavity. It can be anatomically divided into head, corpus, and tail. The pancreatic 
head lies adjacent to the duodenum and is traversed by the ductus choledochus and the 
pancreatic duct, both of which converge in a common structure, the ampulla of Vater, 
whose covering with duodenal mucosa is called the major duodenal papilla. This 
anatomical configuration has important implications for surgical resection of periampullary 
tumors, this being a standard pancreatoduodenectomy, also called Whipple’s procedure. 
A major part of the pancreatic parenchyma is composed of acinar cells that are arranged in 
acini. These produce the digestive enzymes such as lipase, amylase, trypsin, and elastase 
that are secreted into the small intestine and digest the food stuff, breaking down fats, 
carbohydrates, and proteins. The enzymes are secreted in an inactive form and conducted 
from the acini to the ampulla of Vater through the pancreatic ductal system, that is, in a 
highly isolated and compartmented way to prevent leakage and enzymatic activation in the 
parenchyma, which may cause pancreatitis (typically acute), with organ damage and 
inflammation. Together, the acinar tissue and the ductal system form the exocrine 
component of the pancreas. The endocrine component, which represents around 1-2 % of 
the parenchyma, is dominated by the islets of Langerhans that receive 10–15 % of the blood 
flow  (1)  and secrete directly into it hormones such as insulin and glucagon, which are 
important for glucose metabolism. 
1.2 PANCREATIC CANCER 
1.2.1 Epidemiology 
Pancreatic cancer is a pressing health problem, with 459,000 new cases worldwide in 2018 
(2), and around 1,200 in Sweden in 2016 (3). Worldwide, it is the 12th most common 
cancer. Pancreatic cancer is currently the fourth leading cause of cancer-related death in the 
West and predicted to rank second by 2030 (4). Pancreatic ductal adenocarcinoma (PDAC), 
which originates from the exocrine component, is the most common and lethal form of 
pancreatic cancer.  
1.2.2 Risk factors 
Most patients are about 70 years old, both sexes being affected similarly. The main known 
risk factors for development of PDAC are tobacco smoking, obesity, exposure to certain 
chemicals, diabetes (especially new-onset type 2), chronic pancreatitis and family history (5). 
Most cases are sporadic, but about 10 % are linked to inherited mutations in genes such as 
BRCA1 or BRCA2 (hereditary breast and ovarian cancer syndrome), PALB2 (hereditary 
breast cancer), p16/CDKN2A (familial melanoma), FAMMM (familial atypical multiple 
mole melanoma syndrome), MLH1 or MSH2 (hereditary non-polyposis colorectal cancer, 
HNPCC), STK11 (Peutz-Jeghers syndrome), and PRSS1 (familial pancreatitis). 
 
2 
1.2.3 Precursor lesions 
Evidence derived from morphological and genetic analysis of clinical samples and 
genetically engineered mouse models indicates that the development of PDAC follows a 
multistep process with progressive accumulation of mutations. These are reflected at the 
morphological level in premalignant lesions with an increasing grade of dysplasia (low grade 
> high grade) leading eventually to invasive adenocarcinoma. Two main types of precursor 
lesions are recognized (6,7) (Figure 1): the microscopic pancreatic intraepithelial neoplasia 
(PanIN) and the macroscopically evident mucinous cystic neoplasia and intraductal papillary 
mucinous neoplasia (IPMN), of which the latter is the most common and well characterized. 
The canonical neoplastic progression from low-grade PanIN starts with activating oncogenic 
mutation of the KRAS gen followed by mutation of CDKN2A and in high-grade 
dysplasia/PDAC additional mutation of TP53 and/or loss of SMAD4 (8). In contrast, IPMNs 
frequently harbor activating GNAS mutations (9). 
 
Figure 1 - Precursor lesions of PDAC. Left: From Han et al. Recapitulation of complex 
transport and action of drugs at the tumor microenvironment using tumor-microenvironment-
on-chip. Cancer Lett. 2016;380:319-29. Copyright © 2015 Elsevier Ireland Ltd. All rights 
reserved. Right: Photographs courtesy of Prof. Caroline Sophie Verbeke. 
1.2.4 Current treatment 
PDAC is an aggressive type of cancer with a 5-year relative survival rate between 6 and     
9 % in the United States all stages combined (10). The main reasons for the high mortality 
are a late diagnosis and pronounced resistance to treatment. The former is due to the 
absence of specific or sufficiently alarming signs or symptoms in early-stage pancreatic 
cancer (11) and the lack of specific, cost-effective and reliable screening tests (12). The 
most effective treatment is surgical removal of all or part of the pancreas, but unfortunately 
only about 20 % of patients are eligible for surgery (13). In 80 % of patients, the tumor is 
locally too advanced for surgical removal or has spread to the peritoneal cavity or distant 
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parts of the body such as the liver and lungs, precluding a survival benefit from surgery. 
Median survival without surgery is about 3.5 months, while this rises to 15–20 (14) and up 
to 30 (15) months for operated patients. 
Patients are stratified for treatment according to tumor stage and performance status. The 
former is divided into the clinical categories of resectable, borderline resectable, locally 
advanced, and metastatic disease, while the latter is defined according to the Eastern 




2 LITERATURE REVIEW 
2.1.1 Oncological treatment for pancreatic cancer 
Adjuvant chemotherapy is routinely administered after surgery unless the patient cannot 
tolerate it. Gemcitabine (CONKO-001 trial) (16) or fluorouracil (5-FU) plus leucovorin 
(ESPAC-1 trial) (17) for six months have shown a survival benefit of about 10 % compared 
to patients who did not received chemotherapy. Until 2011, monotherapy with gemcitabine 
remained standard of care. More recently, the ESPAC-4 trial has demonstrated a superior 
estimated 5-year survival for combination treatment with gemcitabine and capecitabine 
(GemCap, 28.8 %) compared to gemcitabine only (16.3 %) (18), hence in Sweden, 
GemCap is currently recommended as standard chemotherapy in the adjuvant setting. With 
increasing frequency, neoadjuvant (preoperative) chemotherapy, often with the intensive 
FOLFIRINOX (folinic acid, fluorouracil, irinotecan and oxaliplatin) regimen, is 
administered with the objective to shrink a locally advanced or borderline resectable 
pancreatic tumor (19). Initial reports on the benefit of neoadjuvant therapy for 
borderline/locally advanced pancreatic cancer are promising but await confirmation in 
randomized controlled trials. Lately, a modified FOLFIRINOX regimen in the adjuvant 
setting (PRODIGE 24 trial) (20) has also been demonstrated to result in a significantly 
longer median disease-free survival (21.6 vs 12.8 months) and median overall survival 
(54.4 vs 35 months) among patients with resected pancreatic cancer, compared to 
gemcitabine only, albeit at the expense of a higher incidence of toxic effects. 
Humble progress has also been made during the past years for the majority (80 %) of 
patients with inoperable disease, i.e., with distant metastases and/or local irresectability, 
who generally qualify for systemic palliative chemotherapy. Clinical trials have 
demonstrated a survival benefit for FOLFIRINOX (11.1 vs 6.8 months) (21) or nab-
paclitaxel plus gemcitabine (8.5 vs 6.7 months) (22) versus gemcitabine only. However, 
both combination regimens are associated with substantial toxicity, mainly in the form of 
neutropenia, which limits their use to patients with good performance status without 
relevant comorbidities. This illustrates the urgent need for more effective medical treatment 
strategies, both for first- and second-line therapy, as most patients progress within a few 
months during or after first-line palliative chemotherapy. Novel therapeutic strategies are 
being investigated (23), including pathway inhibitors (ROS1, TRKA-B, and ALK fusions, 
MEK inhibitors), DNA repair (PARP inhibitors for BRCAness phenotypes), 
immunotherapy (PD-L1 and CTLA-4 checkpoint inhibitors, CAR T-cells), cancer cell 
metabolism (mitochondrial tricarboxylic acid cycle) and targeting of the extracellular 
matrix (hyaluronic acid). Unfortunately, most targeted therapies and immunotherapies have 
so far failed to improve survival, but future clinical trials that focus on defined subgroups of 
patients predicted to benefit from these treatments will hopefully overcome the 
disappointing results observed in unselected populations of patients with advanced 
pancreatic cancer. 
2.2 THE TUMOR MICROENVIRONMENT (TME) 
Human PDAC is characterized by the presence of a prominent desmoplastic and 
hypovascular stromal microenvironment that is composed of an admixture of acellular and 
cellular elements, including the extracellular matrix (ECM), mesenchymal cells (mainly 
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cancer associated fibroblasts, CAFs) and immune cells. The TME is a highly dynamic 
milieu in which a complex interplay and molecular signaling cross-talks develop in 
paracrine and autocrine manners with pleiotropic effects on all its components and the 
cancer cells (Figure 2). 
 
Figure 2 - The tumor microenvironment in PDAC. iCAF: inflammatory CAF. mscCAF: 
mesenchymal stem cell-derived CAF. apCAF: antigen presenting CAF. myCAF: 
myofibroblastic CAF. From Hosein et al. Pancreatic cancer stroma: an update on 
therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020 Aug;17:487-505. 
Copyright © 2020, Springer Nature Limited. 
For many years, the TME was regarded as a mere passive bystander. A first shift in the 
paradigm occurred by 2010, when the TME was recognized to have a tumor promoting role 
(24) supporting tumor growth and invasion, e.g., by overexpression of matrix 
metalloproteinases (MMPs, like MMP-2 and MMP-9) that degrade the surrounding ECM, 
or by overexpression of the serine protease inhibitor SERPINE 2 (25) that induces intensive 
ECM production rich in collagen type 1, fibronectin and laminin, resembling the 
desmoplastic reaction observed in PDAC.  
Pancreatic stellate cells (PSCs) emerged as the most important mesenchymal cell type or 
CAF in the TME. PSCs are normally present in the periacinar stroma in a quiescent state 
and store vitamin A droplets. They shift to an activated state in response to cytokines and 
growth factors, like TGF-β, PDGF and FGF-2 that are secreted by inflammatory and cancer 
cells (26), or in response to oxidative stress, caused for instance by the toxic metabolites of 
ethanol in pancreatic acinar cells. Activated PSCs display a myofibroblast phenotype with 
high expression of α-smooth muscle actin (αSMA+) and produce ECM components 
(collagen types 1 and 3, fibronectin, hyaluronic acid) and MMPs. Löhr et at. demonstrated 
that TGF-β1-transfected PDAC cells increased synthesis of extracellular matrix proteins 
including collagen type I on fibroblasts upon stimulation through cocultivation or 
conditioned media, and induced desmoplastic stroma reaction in a xenografted nude mouse 
model (27). The activation of PSCs enables the establishment of paracrine and autocrine 
secretion and signaling loops that perpetuate PSC activation, causing the development of 
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the prominent desmoplastic stromal reaction that is characteristic for PDAC. Activation of 
Hedgehog (HH) signaling through overexpression of HH ligands by cancer cells likewise 
results in activation of PSCs and promotes stromal desmoplasia (28).  
Subsequent studies unveiled several tumor promoting effects of PSCs. Hwang et al. (29) 
showed that PSC-conditioned medium increased proliferation, migration, invasion and 
colony formation in a dose dependent manner in PDAC cell lines, and inhibited the effects 
of chemotherapy and radiation. Furthermore, another study supported a metastasis 
promoting role for PSCs, evidenced by a higher number of metastases in mice injected with 
PDAC cell line plus human PSCs compared to tumor cells only (30). Recently, a potential 
role of PSCs in the impairment of response to chemotherapy has been suggested, due to a 
selective scavenging and accumulation of activated gemcitabine metabolites in PSCs (31), 
which remain sequestered intracellularly and consequently are not made available to tumor 
cells. 
Evidence regarding the active tumor promoting role of CAFs in the TME fueled the interest 
in targeting the stroma as a therapeutic approach for PDAC. The HH signaling pathway 
emerged as a clear candidate due to upregulation of the ligand in PDAC and its 
desmoplasia-promoting effect, but clinical trials on metastatic PDAC investigating the 
addition of HH antagonists to gemcitabine treatment were disappointing (32). Two clinical 
trials showed no benefit compared to gemcitabine alone (33,34), while a third one had to be 
interrupted due to decreased survival in the combination arm. 
Two elegant studies in 2014 fostered a second shift in the TME paradigm. Using different 
approaches in genetically engineered mouse models, both studies showed that depleting the 
stroma is counterproductive as it indeed abolishes the previously unrecognized concomitant 
tumor restraining role of the TME. Rhim et al. (35) depleted PDAC tumors by deleting 
Sonic hedgehog (Shh) ligand, while Özdemir et al. (36) genetically deleted αSMA+ 
myofibroblasts. In both cases the stromal content was reduced, but unexpectedly, this led to 
more aggressive, invasive, proliferating, and undifferentiated tumors and decreased 
survival. Tumors depleted of αSMA+ myofibroblasts showed an increase in the epithelial-
to-mesenchymal transition (EMT) programs, as evidenced by αSMA+ cancer cells and 
enhanced transcriptional expression of the EMT genes TWIST, SNAIL and SLUG. 
A third paradigm shift, partly driven by the groundbreaking advances of immunotherapy in 
other solid tumors like melanoma, lung cancer and mismatch repair (MMR) deficient 
colorectal cancer, was the full recognition of the immune microenvironment as a key 
element of the TME in PDAC and the crucial role of CAFs in governing local immune 
surveillance. 
However, the immune microenvironment in PDAC has unique characteristics (37): 
 In contrast to other solid cancers, which may display substantial lymphocytic 
infiltration, the number of intratumoral effector T-cells is low.  
 The RAS oncogene is associated with activation of inflammatory pathways in which 
Cox2, IL-6 and its downstream effector phospho-Stat3 are overexpressed (38). This 
creates a persistent tumor-associated chronic inflammatory micromilieu. 
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 Infiltrates of myeloid derived suppressor cells (MDSCs) play a direct role in immune 
suppression, promoting unrestricted cancer cell growth.  
 Finally, PDAC cells grow in an extensive and dense fibrous stroma that constitutes a 
barrier to the recruitment of immune cells.  
The interplay between two fundamental immunological processes, the effector, and the 
suppressor, determines the immune response against cancer cells: 
 Effector immune cells: 
o CD8+ cytotoxic and CD4+ helper T-cells - tumor infiltrating lymphocytes 
(TILs): TILs are the most important anti-tumor immune elements in the TME. 
High numbers of CD8+ and CD4+ T-cells are associated with a longer survival 
in PDAC (39,40), but their numbers are usually low, probably due to the 
effect of the stroma, CAFs (41) and suppressor immune cells.  The CD45RO+ 
memory CD8+ T-cells are considered to be the major anti-tumor effector cells. 
Among CD4+ cells, the effector Th1 cells (Tbet+) activate antigen presenting 
cells, like dendritic cells, to potentiate the presentation of tumor antigens to 
cytotoxic T-cells. In contrast, Th2 cells (GATA3+) have been suggested to 
induce tumor tolerance. Disproportionately high ratios of Th2 / Th1 have been 
reported in PDAC, associated with a reduced survival (42), indicative of an 
ineffective immune response against the cancer cells (43). Interestingly, the 
Th2 cell polarization was mediated by thymic stromal lymphopoietin (TSLP) 
secreted by CAFs, an observation that illustrates well the complex cross-talk 
between tumor cells, CAFs and immune cells in the TME. 
o Natural killer cells (NK): Are divided into two types.  
▪ Type I (invariant): Recognize and eliminate cancer cells, mainly by 
binding of Natural Killer Group 2, member D (NKG2D) activating 
receptor to the ligand MHC class I chain A (MICA) that is expressed 
on epithelial tumors, including PDAC. But tumor cells can express 
and secrete into the serum sMICA, a cleaved product of MICA after 
proteolytic shedding. Higher serum levels of sMICA showed 
significant inverse correlation with NKG2D expression in NK cells 
and moreover, these were functionally impaired, not capable of killing 
PDAC cells (44). Evidence indicates that expression of sMICA by the 
tumor cells may represent an immune evasion mechanism that leads to 
the impairment of immunosurveillance by NK cells and/or CD8 
cytotoxic- and γδ-T cells, which also express NKG2D. 
▪ Type 2: Promote tumor progression by producing IL-13, which in turn 
induces accumulation of MDSCs and/or polarizes macrophages 





 Suppressor immune cells: 
o T-regulatory cells (CD4+, CD25+, FoxP3+): Exert immunosuppressive activity 
through the release of cytokines, including TGF-β and IL-10. As previously 
noted, the ineffective form CD4+ Th2 plays a major role in tumor tolerance. 
o Tumor associated macrophages (TAMs): Are divided into two phenotypes 
(45): 
▪ M1 (classical) macrophages: Highly inflammatory and effective in 
promoting activation of immune cells capable of killing cells. 
Generate high levels of pro-inflammatory cytokines such as IL-12 and 
low amounts of IL-10, which promotes the differentiation of CD4+ T 
cells into Th1 cells and activated cytotoxic CD8+ T cells. 
▪ M2 (alternative) macrophages: Inhibit inflammatory responses and 
adaptive Th1 immunity. Promote angiogenesis and tumor 
development. Generate low levels of IL-12 and high of IL-10. 
▪ Extensive TAM infiltration is generally associated with a poor 
prognosis in several human cancers. One important mechanism of 
tumor immune scape is through the expression of the programmed 
death ligand 1 (PD-L1) by macrophages that binds to PD-1, an 
inhibitory receptor that leads to induction of apoptosis in activated T-
cells. 
o Myeloid derived suppressor cells (MDSCs): Comprise a heterogeneous 
population of immature myeloid cells precursors of dendritic cells, 
macrophages, and granulocytes (46). MDSCs are driven by tumor-secreted 
factors, in particular GM-CSF that promotes recruitment of myeloid 
progenitor cells and their differentiation into MDSCs. MDSCs perturb both 
the innate and adaptive (CD4+ and CD8+ T cell activation) immune responses 
and evidence indicates that are potent inhibitors of antitumor immunity in-
vivo. Treatments that reduce MDSCs such as gemcitabine and surgical 
resection, which reduce the tumor mass, also contribute to restore immune 
surveillance and activate T and NK cells.  
 Cancer associated fibroblasts: 
o Pancreatic stellate cells (PSCs): It has been suggested that PSCs play a role in 
regulating the immune response to the tumor (26). PSCs promote the 
differentiation of peripheral blood monocytes into MDSCs through activation 
of STAT3 signaling by PSC-derived IL-6 (47). Activated PSCs express high 
levels of galectin-1, which impairs survival of T cells (48). It has also been 
suggested that PSCs can attract and sequester CD8+ T cells via the 
CXCL12/CXCR4 axis, reducing their migration to the juxtatumoral stromal 
compartment and impeding their contact with the tumor cells (49). 
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o FAP+ cancer associated fibroblasts (CAFs): These CAFs were found to 
contribute to an immunosuppressive TME and resistance to checkpoint 
antagonists in a GEMM of PDAC by production of  the chemokine CXCL12 
(50). Depletion of the FAP+ cells uncovered the antitumoral effects of anti-
CTLA-4 and anti-PD-L1 drugs that otherwise failed in this model, while 
treatment with an inhibitor of the CXCL12 receptor CXCR4 induced T-cell 
accumulation around cancer cells and a synergistic antitumoral effect with 
anti-PD-L1.  
o Pancreatic CAFs have also been shown to suppress T cell proliferation and 
proinflammatory cytokine release and to promote the expression of co-
inhibitory markers, such as PD-1 and TIM-3, on activated T cells (41). 
The latter studies highlight, in a subsequent shift of the TME’s paradigm, the phenotypic 
heterogeneity of the stroma and CAF subpopulations and the need to gain deeper 
knowledge as a means to open the path for novel therapeutic approaches aimed at 
reprogramming rather than depleting the stroma and promoting the more tumor-restraining 
stromal phenotypes (32).  
Following this line of investigation, a growing body of research describes several partially 
overlapping stroma subtypes based on transcriptional profiling or histomorphology that are 
associated with differences in prognosis: 
 Erkan et al. (51) showed that the activated stroma index, determined as the the ratio of 
α-SMA (marker of PSC activity) to collagen (deposition) stained area, was an 
independent prognostic factor associated with a shorter survival. 
 ”Activated” vs “classical” (52): 
o “Classical” stroma: Is characterized by high numbers of PSCs expressing α-
SMA, desmin and vimentin and associated with a more favorable survival 
(median 24 months). 
o “Activated” stroma: Proinflammatory, contains large numbers of 
macrophages, shows upregulation of chemokine ligands (like CCL13 and 
CCL18) and is associated with a shorter survival (median 15 months). 
 “Mature”, “intermediate”, “immature” (53): 
o “Mature” stroma: Contains a dense amount of collagen fibers and low number 
of CAFs.  
o “Immature” stroma: Is highly cellular and collagen poor; was associated with 
a poorer survival. 
o “Intermediate” stroma: Between the mature and immature types. 
 “(Highly) stiff” stroma (54): Defined by matricellular-enriched fibrosis with high 
tissue tension, was associated with reduced TGF-β signaling, elevated β-integrin 
mechano-signaling and epithelial STAT3 activation, resulting in accelerated tumor 
progression and shortened survival. 
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Evidence indicates that different CAF subpopulations determine the diverging stroma 
subtypes (55–59): 
 Several “general” CAF markers have been identified, like collagen type I alpha 1 
chain, fibroblast activation protein alpha (FAP-α), vimentin, decorin and podoplanin 
(D2-40). 
 “Myofibroblastic” CAFs: Tumor restraining. Located immediately adjacent to and 
surrounding the cancer cell clusters. These are induced by tumor-secreted TGFβ and 
activation of the TGFβ / SMAD2/3 pathway in CAFs. Show high α-SMA expression, 
active HH signaling and upregulation of pathways related to smooth muscle 
contraction, focal adhesion, ECM organization, collagen formation and promotion of 
mesenchymal phenotype. 
 “Inflammatory” CAFs: Tumor promoting. Located more at a distanc from the cancer 
cells, distributed throughout the tumor field. Induced by tumor secreted IL-1/JAK-
STAT3 pathway activation in CAFs. Show low α-SMA and secrete inflammatory 
cytokines such as IL-6, IL-11 and LIF, chemokines, matrix remodeling proteins and 
growth factors. Inflammatory CAFs show upregulation of inflammatory pathways 
such as IFNγ response, TNF/NF-κB, IL2/STAT5, IL6/JAK/STAT3, and complement. 
Exhibit specific expression of hyaluronan synthases (HAS1, HAS2). Hyaluronan, a 
major component of the ECM, has been identified as a major source of solid tumor 
stress impairing vascular perfusion and compromising drug delivery. Transcriptomic 
analysis revealed type 1 receptor for angiotensin II as a marker of inflammatory 
CAFs, which could be associated with the reduction in solid stress and improved 
survival observed in murine models of PDAC following treatment with Losartan, an 
inhibitor of this receptor (60,61), which is currently being investigated as part of 
combination treatment in clinical trials (NCT01821729, NCT03563248). 
 Öhlund et al. showed that PSCs plated in Matrigel induced quiescent PSCs and that 
these could transdifferentiate either into inflammatory CAFs when co-cultured with 
PDAC organoid-conditioned medium or into myofibroblastic CAFs when cultured in 
two-dimensional monolayers (57). Remarkably, the CAF phenotypes were mutually 
exclusive but dynamically reversible according to the culture conditions, indicative of 
phenotypic CAF plasticity. Along with this line, a recent study by Liu et al. (62) 
performed comprehensive transcriptomic analyses in a 3D spheroid model of PSC 
and PDAC. They showed than when co-cultured in heterospheroids, PSCs shifted 
from myofibroblastic to inflammatory CAF phenotype, while PDAC cells did from a 
classical/progenitor to a basal-like/squamous subtype, and their sensitivity to 
gemcitabine was increased. 
 “Antigen presenting” CAFs: Single cell transcriptomic analysis of human and murine 
PDAC revealed the presence of a further distinct CAF subpopulation that expresses 
MHC class II and CD74, but not classical co-stimulatory molecules, suggesting that 
they contribute to the immune suppressive microenvironment by inducing anergy or 
Treg differentiation of CD4+ T cells (55). 
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Another subtype of CD10+ CAFs was previously described, with increased secretion of 
matrix metalloproteases and associated with enhanced cancer progression (63). It is 
expected that additional subpopulations of CAFs will be described in future studies as well 
as potential therapeutic approaches targeting pro-tumorigenic signaling pathways in CAFs.  
In this context, much of the research on PDAC-stroma interactions and stroma targeting 
relies on in-vitro studies with (co)cultures of PSCs. As shown by Lenggenhager et al. (64) 
PSCs from different origins and conditions (human/murine, primary/immortalized, from 
normal pancreas/chronic pancreatitis/PDAC) show diverging phenotypes and functional 
traits, such that selection of the most suitable and biologically relevant PSC must be 
considered carefully based on the specific research questions and experimental setting. 
2.3 MORPHOLOGICAL HETEROGENEITY IN PANCREATIC CANCER 
Morphological diversity is a prominent but barely investigated feature of PDAC (65). It 
presents both at inter- and intratumoral levels and is likely to reflect key biological features 
of the cancer cells and the tumor microenvironment, such as mutational landscape, 
epigenetic alterations, and distinct cross-talks in the diverse stromal compartments, like the 
pancreatic stroma, duodenal wall, peripancreatic fat tissue, perineural space, and lymphatic 
and blood vessels. Ligorio et al. (66) demonstrated functionally and analytically the 
influence of the stroma on  shaping glandular composition in PDAC with respect to 
epithelial-mesenchymal transition (EMT) and proliferative (PRO) cancer cell phenotypes. 
The cancer cells were dominated by a double negative EMT-/PRO- phenotype when 
cultured in absence of CAFs, shifted towards EMT+ and PRO+ phenotypes when 
cocultured with CAFs and peaked in double positive EMT+/PRO+ cancer cells when CAFs 
outnumbered the cancer cells in coculture. EMT and PRO phenotypes were linked to 
activation of MAPK and STAT3 signaling pathways in the cancer cells and secretion of 
TGF-β1 by the CAFs. Investigation of a clinical cohort of primary PDAC showed, in line 
with the preclinical results, that glands dominated by double positive EMT+/PRO+ cells 
were enriched in tumors with high stroma content, EMT+ containing glands in tumors with 
medium stroma content, and PRO+ glands in tumors with low stroma. In a recent study, 
Sántha (67) et al. described four common patterns of pancreatic cancer (periglandular, 
tendon-like, fascicular, and chickenwire) with distinctive morphological configurations and 
(immuno)-histochemical features of the tumor glands and their respective cancer-associated 
stroma. These findings further support a correlation of morphological heterogeneity with 
structural and functional diversity in pancreatic cancer. 
Although the complete spectrum of morphological diversity in PDAC is not yet fully 
catalogued, it is partly reflected in the WHO classification (68). The latter roughly 
distinguishes between “subtypes” and “patterns”, where only the former ones are 
encouraged to be reported by pathologists, as these have been associated with differences in 
prognosis and may harbor different molecular signatures. Noteworthy, most of the 
morphological subtypes and patterns were described mostly on a morphological basis, in 
single studies, on small cohorts, between 1984 and 2012, and have not been further revised 
or followed up by continuation studies. 
The PDAC subtypes include anaplastic (69), adenosquamous (70), hepatoid (71), medullary 
(72), undifferentiated with osteoclast-like giant cells (73), signet ring (74), colloid (75), and 
invasive micropapillary (76). Among them, the anaplastic, adenosquamous and hepatoid 
subtypes have been associated with a worse prognosis, while a fraction of medullary 
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carcinomas are MMR-deficient and may be associated with hereditary nonpolyposis 
colorectal cancer (HNPCC) or EBV infection. 
Described PDAC patterns include large duct (77), foamy-gland (78), clear cell (HNF-1β+) 
(79), microcystic/vacuolated (80), paucicellular infiltrating (81), and cystic papillary (82). 
As their reporting is not included in the current pathology guidelines, the incidence and 
potential prognostic and therapeutic implications are largely unknown. Reporting of 
histological subtypes is also challenging due to intratumoral heterogeneity and co-
occurrence of multiple subtypes in the same tumor, histomorphologies that do not fit in the 
described categories above, the inherent difficulty of manually quantitating histological 
components by light microscopy, sampling bias, and the lack of established systems for 
scoring/assessment. 
More thoroughly studied is the impact of an intestinal versus pancreatobiliary type of 
differentiation in adenocarcinomas from the periampullary region, including PDAC. The 
intestinal subtype, whose morphology resembles that of colorectal cancer, was first 
described in PDAC by Albores-Saavedra et al. (83). It is composed of tubular, 
simple/branching/cystically dilated glands with foci of cribiform structures. Intestinal-type 
tumor cells are tall columnar, with a variable amount of cytoplasmic mucin and admixed 
collections of goblet cells. Nuclei are typically ovoid/elongated, hyperchromatic/vesicular 
and pseudostratified. By contrast, conventional pancreatobiliary-type adenocarcinoma 
grows in simple/branching glands and small, solid tumor cell nests. The cells are 
cuboidal/low columnar and single layered. The nuclei are round, with marked variation in 
size and shape and lack pseudostratification. However, “mixed” and “hybrid” 
histomorphological features can hamper reproducibility and definite tumor subtyping (84). 
Immunohistochemical staining is helpful to distinguish between intestinal and 
pancreatobiliary type tumors (85,86). Intestinal-type adenocarcinomas express CK20, 
MUC2 and CDX2, while those of the pancreatobiliary type are immunoreactive for CK17, 
MUC1, MUC4, MUC5AC, CA19-9 and CA125. However, a fraction of periampullary 
adenocarcinomas may show also at the immunohistochemical level “mixed” 
immunoprofiles. 
Multiple studies have shown that periampullary adenocarcinomas of the intestinal type, and 
in particular those arising from the ampulla of Vater, have a better prognosis than those of 
the pancreatobiliary type (85,87,88). Interestingly, a number of studies (87,88) found that 
the histological type of differentiation, rather than the primary tumor location, was an 
independent predictor of survival on multivariate analysis. Altogether, evidence indicates 
that intestinal and pancreatobiliary tumors potentially represent distinct diseases with 
therapeutic implications and that the histological type of differentiation should be 
accounted for when interpreting past clinical trials and for future trial design (89). 
2.4 MOLECULAR HETEROGENEITY IN PANCREATIC CANCER 
PDAC is presently recognized as a heterogenous disease and efforts to establish molecular 
subtypes that predict therapeutic responses and guide clinical decision making are currently 
under intensive investigation (90). A large integrated genomic analysis with 
histopathological correlation (91) identified four subtypes: squamous, associated with the 
adenosquamous variant of PDAC; pancreatic progenitor; immunogenic, associated with 
upregulation of immune networks, including acquired immune suppressive pathways; and 
aberrantly differentiated endocrine-exocrine. In another study, Moffit et al. (52) identified 
 
14 
based on gene expression analysis two subtypes of PDAC: (i) a classical (pancreatic) 
subtype, characterized by upregulation of genes like CEACAM6 and KRT20, associated 
with a better survival, and (ii) a basal-like subtype, that is characterized by upregulation of 
KRT17, KRT15, KRT6A, SERPINB3 and S100A and associated with a significantly worse 
overall survival. Recently, Chan-Seng-Yue et al. (92) performed whole genome and bulk 
transcriptome analysis in a large cohort of resectable (stage I/II) and advanced (stage III/IV) 
PDAC. Both subtypes were subdivided further into categories A and B. Classical-A/B 
tumors were characterized by upregulation of transcription factors related to pancreatic 
lineage differentiation, like GATA6, HNF1A and HNF4G, and were more frequent in early 
stage (I/II). The classical-A subtype showed lower frequency of intact SMAD4. Basal-like 
subtypes, in which expression of classical transcription factors is lost, showed a diverging 
distribution, being basal-like-A more frequent in stage IV (metastatic disease) and 
associated with a high chemoresistance; while basal-like-B was more frequent in early 
stage (resectable). Single cell RNA-seq, performed in a subset of tumors, showed that both 
basal-like and classical cell populations often co-exist in different proportions within the 
same tumor, creating a transcriptional continuum at the bulk transcriptome level. Kalimuthu 
et al. (93) assessed a series of resected PDAC with matched transcriptome data and 
classified them into two morphological categories, ‘gland forming’ (comprising 
conventional and tubulopapillary) and ‘non-gland forming’ (comprising composite and 
squamous). Guided by transcriptome data, a cutpoint of 40 % gland formation was chosen 
to divide the tumors into these two groups, which correlated with the classical and basal-
like molecular subtypes and differed in overall survival. This study supports the possibility 
of linking the established molecular subtypes with morphology-based assessments, which 
are easier to be adopted into routine clinical practice. 
Several molecular classification systems have been proposed. Very recently, the division 
into two categories have been challenged by studies that show marked intratumor 
heterogeneity, such that a “molecular gradient” rather than discrete molecular categories 
has been proposed (94). 
Molecular classifiers for prediction of response to therapy in the context of precision 
medicine are also beginning to emerge. In a comprehensive multicenter study, Tiriac et al. 
(95) generated a large library of PDAC patient derived organoids, which allowed the 
evaluation of responses to a panel of chemotherapeutic drugs (“pharmacotyping”). In 
addition to classifying the patient derived organoids into classic and basal-like subtypes, 
transcriptomic analysis identified a gemcitabine-sensitivity signature that stratified patients 
according to response status to adjuvant gemcitabine.  
2.5 EX-VIVO ORGANOTYPIC SLICE CULTURE  
Cultured tissue slices have been used since 1923 for studies on liver metabolism or 
transport processes in the kidney and became more widespread as an in-vitro tool to study 
metabolism and toxicity in various organs after the introduction of the Krumdieck tissue 
slicer. Tissue slicers allow the production of precision-cut tissue slices of a consistent 
thickness with minimal cutting-induced damage (96). The cultured tissue slices can then be 
submitted to any possible analytical method. 
When it comes to cancer, during the past decade a progressively growing body of literature 
has used precision-cut tissue slices from different tumor types to address key questions 
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related to oncogenic signaling pathways (97), intratumoral heterogeneity, drug sensitivity 
testing and immunotherapy. The main advantages of the tissue slices, in contrast to 
traditional cell cultures (2D, 3D, organoids), xenograft-based or genetically engineered 
mouse models are the preservation of the native tumor microenvironment and the 3-
dimensional tissue architecture that render this model a close surrogate to the parent tumor. 
The biological relevance of the 3D tumor configuration and the reciprocal influences with 
the stroma has also been highlighted by in-vitro studies on cell lines. Our group showed 
that PDAC cell lines cultured as 3D spheroids versus in 2D showed upregulation of 
extracellular matrix and chemoresistance related genes, as well as increased resistance to a 
panel of drugs, including gemcitabine (98). In a continuation study, PDAC cells co-cultured 
with PSCs in 3D spheroids demonstrated increased proliferation and shift towards a more 
mesenchymal phenotype, while PSCs showed activation and shift towards a myofibroblast 
phenotype, as compared to spheroid monocultures (99). 
The ultimate goal of the slice culture is to mimic as closely as possible the in-vivo situation 
as a means to narrow the current enormous gap between preclinical and clinical results and 
hence be able to predict drug responses in a reliable and reproducible way. These features 
render the slice culture a state of the art low-throughput but high-content experimental 
platform for drug testing and investigation of tumor biology. 
 
2.5.1 General workflow for ex-vivo organotypic slice cultures in the literature 
Soft and fatty tissues, such as breast tissue, were previously embedded in low melting point 
agarose to improve the success rate of the slicing process (100). Slicing was performed 
using a vibrating blade microtome (Leica VT, Krumdieck) or a tissue chopper (101). 
Typical culture time was about one week. Tissue slices were most often cultured at 
atmospheric condition (21 % O2), with 5 % CO2 and at 37 °C (97). Systematic optimization 
procedures identified the use of semipermeable inserts as an important factor to improve 
tissue viability. After harvesting, preservation of the native tumor histomorphology was 
assessed by light microscopy and comparison with the non-cultured/parent tumor. Tissue 
viability during culture and cancer cell viability after drug exposure were assessed by 
combination of morphology-based techniques and biochemical assays. Morphological 
techniques and molecular analyses were used for the assessment of signaling pathways 
(102). 
2.5.2 Organotypic slice cultures of the pancreas 
Pancreatic studies based on precision-cut tissue slices have focused mainly on investigating 
the transfection efficacy for viral-vector-mediated gene therapy (103), stress-mediated 
activation of PSCs (104), and physiology of acinar cells and islets of Langerhans (105). 
Recently, our group has published a study (106) presenting an optimized protocol for 
culturing precision-cut tissue slices from human PDAC during at least 4 days with 
subsequent thorough histomorphological and immunohistochemical characterizations of the 
tumor cells and the tumor microenvironment. We showed that the grade of tumor 
differentiation remained unaltered during culture inclusive in a progressive cell outgrowth 
occurring on the surface of the tissue slices, and that proliferation was maintained. 
When it comes to therapeutics, Jiang et al. (107) showed viability and preservation of the 
tumor, stroma and immune microenvironment in precision-cut slices of human PDAC for 
up to 6 days. Recapitulation of the cytotoxic effects of drug treatment was demonstrated by 
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exposing the tissue slices to staurosporine, a protein kinase inhibitor and inductor of 
apoptosis, and cycloheximide, an inhibitor of protein biosynthesis. After 48 h of treatment, 
the percentage of Ki67+ cells was slightly decreased, while the total number of nuclei 
(cellularity) was diminished and the percentage of cleaved caspase-3 cells markedly 
increased, as assessed by brightfield immunohistochemistry. Cytotoxic effects to treatment 
were time- and dose-dependent. The three-dimensional spatial relationship between live-
stained EPCAM+ tumor cells and CD8+ cytotoxic T-cells or fibronectin and CD11+ 
macrophages could be imaged after fixation by confocal microscopy. Migration of 
autologous CFSE-labelled splenocytes into co-cultured tissue slices was also demonstrated. 
In another study based on live and time-lapse fluorescent microscopy, Seo et al. (108) 
demonstrated reactivation, expansion, mobilization and tumor cell killing   by resident 
CD8+ T-cell clones in tissue slices of human PDAC following combination treatment with 
anti-PD1 and anti-CXCR4 antibodies. Supernatant from cultures showed presence at base 
line of CXCL12, the soluble ligand of CXCR4, which has been associated with an 
immunosuppressive microenvironment in multiple carcinoma types; and granzyme B and 
IFNγ effector molecules after combination therapy, suggesting active tumor cell killing. 
Combination treatment induced migration and relocation of CD8+ T-cells into the 
juxtatumoral stroma containing EPCAM+ cells. This was associated with a marked increase 
in tumor cell apoptosis, evidenced by SR-FLICA labeling of activated caspase-3 and -7 
enzymes. The presence of clonally expanded T-cells within the PDAC microenvironment 
together with the synergistic effects of combined PD-1 and CXCR4 blockage argues 
against the concept of PDAC being an immunologically “cold” tumor. Rather, it supports 
the important role of the stroma in the sequestration and inactivation of tumor-reactive T 
cells and highlights the future prospect of developing effective immunotherapies against 
PDAC and other tumors showing immune exclusion. 
2.5.3 Methodological aspects of ex-vivo tissue slice cultures of tumor types 
other than pancreas 
Tissues slices have been used to investigate drug effects in breast cancer (100,109), 
glioblastoma (101,110), head and neck squamous cell carcinoma (111,112), gastric-
esophagogastric junction cancer (113), and lung cancer (114). 
Ex-vivo tissue slices allow testing of both simple and complex chemotherapy treatments, 
albeit with a single dose retaining the clinical ratio of its components. The optimal doses for 
ex-vivo experiments can be determined according to turning points for toxicity that have 
been established in previous cell culture experiments testing various concentrations and 
lengths of continuous drug exposure (109). Targeted drugs, like KRAS signaling inhibitors, 
have also successfully been investigated in tissue slices, where the cytotoxic drug responses 
correlated with the spatial signaling heterogeneity of the targeted pathways as assessed by 
immunohistochemistry (114). 
Relevant readouts for evaluation of drug effect when comparing matched treated and 
untreated tissue slices were tumor cell content (112,114), tumor cell proliferation, cell 
death, and functional assays of cell viability like WST and ATP-utilization (112). Tumor 
cell content can be evaluated as the percentage of the tumor cell area with respect to the 
tissue slice. A pathologist can manually annotate non-viable tissue areas in digital 
histological slides. In addition, relative decrease in viability (expressed as percentage) can 
be calculated according to the formula: (1 – viability in drug treated / viability in untreated 
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control) * 100. The cytotoxic drug effect can then be plotted with a line representing the % 
of viable area in treated vs untreated slices (114). Tumor cell proliferation is commonly 
assessed by Ki67 immunostaining, which can be combined with CK19 or vimentin for a 
more precise discrimination between cancer cells and stroma/immune cells. Alternatively, 
immunofluorescence for EdU incorporation allows real time measurement of DNA 
synthesis. Cell death is detected on routine histology by the appearance of distinct nuclear 
and cytologic changes: karyolysis, pyknosis, karyorrhexis and apoptotic bodies. However, 
its quantification may require the use of special labelling techniques like TUNEL, γH2AX 
(immunohistochemistry, DNA double strand breaks) (115), cleaved cytokeratin 18 (M30) 
or activated caspase-3 (116). Propidium iodide (PI) can also be used to label necrotic cells 
on immunofluorescence. 
Ex-vivo cultured tumors can then be classified into responders and non-responders to 
specific drugs according to the assessed readouts. Combining readouts from different levels 
(cell viability, histomorphology, proliferation and apoptosis) may increase the robustness of 
the classification and prediction models. 
The predictive ability of slice culture for testing cytotoxic and targeted therapeutics can 
ultimately be validated by correlating the effects (according to readouts) in the tissue slices 
with the responses observed in human tumor-derived xenotransplants and in patient cohorts 
(112). 
2.6 SELENIUM COMPOUNDS AS POTENTIAL CHEMOTHERAPEUTIC DRUGS 
Selenium is an essential micronutrient found in many food sources, mainly breads, grains, 
meat, poultry, fish, and eggs (117).  In adults, its daily requirement and upper safe levels of 
intake are 55 µg and 400 µg, respectively (118). Selenium deficiency is linked to a juvenile 
type of cardiomyopathy (Keshan disease) (119), while excess intake is toxic and can cause 
skin, neurological and gastrointestinal symptoms. Selenium is a key component of the family 
of selenocysteine (amino acid) containing selenoproteins. These play important roles in 
cellular antioxidant defense, redox homeostasis, male fertility, and thyroid function (120).  
Redox-active selenium compounds are interesting candidate treatments for PDAC, as it has 
been shown by our group and others (121) that cancer cells, and in particular those that show 
resistance to conventional chemotherapeutics, are specifically sensitive to pharmacological 
modulations of redox states. 
Cancer cells have an altered redox status that is characterized by higher rate of ROS 
production. This results in hyperactivation of pro-tumorigenic signaling pathways including 
proliferation, survival, and metabolic adaptation to the microenvironment. At the same time, 
higher ROS levels are toxic and can trigger cell death, senescence and proliferation arrest, 
such that cancer cells rely on higher levels of antioxidant proteins to maintain redox 
homeostasis (122). This, so called antioxidant response element (ARE) (123), induces 
proteins that mediate cellular detoxification and protection from oxidative stress, but also are 
associated with the development of resistance to conventional chemotherapeutic drugs. This 
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occurs e.g. by induction of multiresistance proteins (MRPs) and X-c cystine/glutamate 
antiporter expression that increases intracellular glutathione (GSH) levels (124).  
Selenium compounds show high uptake in the pancreas, liver and kidney after oral 
administration (125). Sodium selenite (Se), an inorganic form of selenium, was previously 
shown that exerts a cancer-specific cytotoxic effect against different malignant cell lines and 
in particular against drug-resistant tumor cells (126,127). The tumor-selective cytotoxicity of 
Se is mediated by a high-affinity uptake of a reduced form of Se that is increased by X-c 
cystine/glutamate antiporter and MRP activity, together with highly increased oxidative stress 
due to redox-cycles of low-molecular-weight selenolates with intracellular thiols and oxygen. 
These cycles, sustained by intracellular glutathione (GSH) or the thioredoxin system, are very 
efficient and produce high levels of ROS that can overcome redox homeostasis and induce 
cytotoxic cell death in the cancer cells (128). 
In contrast, methylselenocystein (MSC), an organic form of selenium, is biologically inert 
and can be considered as a pro-drug. MSC is metabolized in several organs including the 
pancreas and liver by the enzyme kynurenine aminotransferase 1 (KYAT1) into 
monomethylselenol (β-elimination product) and β-methylselenopyruvate (transamination 
product) (129). Monomethylselenol is highly redox-active and has been shown cytotoxic, 
antiproliferative, and proapoptotic properties in different malignant cell lines (130,131). 
While the α-keto acid metabolite β-methylselenopyruvate was reported to exert anti-tumor 
effects through inhibition of HDAC activity (132,133), which promotes proliferation, 
invasion and resistance to gemcitabine in pancreatic cancer cell lines through histone 
modifications (134). It has been further suggested that combination of MSC with an α-keto 
acid like phenylpyruvic acid (PPA) or indole-3-pyruvic acid (IPA) may have a synergistic 
effect and potentiate the cytotoxicity of MSC by increasing its β-elimination and reducing its 
transamination by KYAT1 (135). 
Our group has carried out a phase I clinical trial where selenite was administered intravenous 
to cancer patients refractory to cytostatic drugs (136). Selenite was found to be safe and 











3 RESEARCH AIMS 
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with an overall 5-year 
survival < 9 %. Despite increasing knowledge regarding the biology of PDAC, improvement 
of treatment efficacy has been disappointingly small over the past decades. Two factors that 
likely may have hampered therapeutic advances are the traditional concept of PDAC as a 
homogenous disease and the limitation of experimental models for drug discovery to cell 
lines and xenograft mouse models, which only to a limited grade mimic human PDAC.  
The overall aims of this thesis were to advance the field by addressing these questions, by (i) 
investigating tumor subtypes at the immunohistochemical level and analyzing the association 
with patient survival, and by (ii) establishing a novel, ex-vivo experimental model based on 
precision-cut tissue slices of human pancreatic cancer as a close surrogate for the parent 
tumor. 
Thus, the specific aims for the individual studies were as follows: 
1. To develop an integrative immunohistochemical classification of adenocarcinomas of 
the pancreatobiliary system to improve diagnosis and prognostic stratification. To 
specifically investigate the immunohistochemical diagnosis and prognostic 
significance of the intestinal and pancreatobiliary adenocarcinoma subtypes. 
2. To establish an ex-vivo, precision-cut tissue slice model of human PDAC, to optimize 
culture conditions for keeping slices viable for at least 96 h, and to investigate the 
structural and functional integrity of the constituting neoplastic and non-neoplastic 
tissues by morphology-based techniques. 
3. To further characterize the established precision-cut tissue slice model of human 
PDAC at the whole transcriptome level and investigate the value of transcriptomic 
analysis for the evaluation of the level of preservation of the tissue slices. 
4. To investigate the use of the established precision-cut tissue slice model of human 
PDAC for drug sensitivity testing, and specifically, to investigate the potential of 





4 MATERIALS AND METHODS 
 
Work 1 (“Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary 
System Improves Diagnosis and Prognostic Stratification”) was a retrospective 
observational cohort study. The series comprised patients who underwent diagnostic core 
needle biopsy or surgical resection at Karolinska University Hospital between the years 
2002 and 2013 for primary adenocarcinoma in the pancreatobiliary system, including 
PDAC, ampullary carcinoma, distal bile duct cancer, perihilar cholangiocarcinoma, and 
intrahepatic cholangiocarcinoma. A series of hepatocellular carcinomas were also included 
as a control group. The study included adenocarcinomas and histological variants, as 
defined by the World Health Organization (WHO) classification 2010 (137). However, 
adenosquamous carcinomas were excluded, to avoid excessive study complexity. 
A total of 409 tumor samples from 370 patients were analyzed. For each sample, a 
representative block was stained with a comprehensive panel of immunohistochemical 
markers that are widely used in diagnostic pathology, according to established clinical 
diagnostic routines at Karolinska University Hospital.  The panel for analysis comprised up 
to 27 immunohistochemical markers, including intermediate filaments (CK5, CK7, CK17, 
CK18, CK19, CK20, vimentin), mucins (MUC1, MUC2, MUC5AC, MUC6), markers 
usually expressed in adenocarcinomas of gastrointestinal and pancreatobiliary origin 
(BerEP4, EMA, CEA, CA19-9, CA125, maspin, CDX2), CD56, tumor suppressors (P53, 
SMAD4) and proliferation (Ki67). Immunohistochemical staining was scored quantitatively 
according to the percentage of positively stained tumor cells by visual assessment. 
Clinicopathological and outcome data were retrieved from the hospital medical records. 
An omics-type bioinformatic analysis was performed using R software for statistical 
computing (version 3.0.2), the main steps being: data preprocessing, unsupervised 
clustering (hierarchical and complex network based), differential expression analysis, 
graphical visualizations (immunohistogram and complex network based), internal model 
validation, and survival analysis. Complex networks were generated using Gephi (version 
0.8.2-beta).  For differential expression, only the markers that were found to be significant 
by three different non-parametric methods, RankProd, SAM, and MultTest, were 
considered. An overview of the data analysis pipeline is shown in Figure 3. Internal model 
validation was based on machine learning classifiers using Weka (version 3.6.9). Survival 
analysis for mortality was performed using Kaplan–Meier curves and univariate (crude) and 
multivariate (adjusted) Cox proportional hazards regression models with p-values, hazard 
ratios (HR) and 95 % confidence intervals (CI). In multivariate analysis, the 
immunohistochemical or anatomically based tumor types were adjusted for tumor stage 
(pT) and lymph node status (pN).  The Cox models’ proportional hazards assumption was 
tested. The complete dataset, R code and reproducible computer environment for the 




Figure 3 - Schematic overview of the data analysis pipeline. From Fernández Moro C et al. 
Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves 
Diagnosis and Prognostic Stratification. PloS One. 2016;11:e0166067. Copyright © 2016 
Fernández Moro C et al. CC-BY. 
  
Work 2 (“Ex-Vivo Organotypic Culture System of Precision-Cut Slices of Human 
Pancreatic Ductal Adenocarcinoma”) was a prospective preclinical experimental study. 
PDAC tumor samples from 12 chemonaïve patients operated at Karolinska University 
Hospital were cultured, comprising 4 well differentiated, 6 moderately-to-poorly 
differentiated and 2 non-gland forming, poorly differentiated carcinomas.  
Fresh tumor tissue samples, between 5 and 10 mm in size, were obtained from surgical 
specimens immediately following resection.  While being submerged in ice-cold medium, 
the tissue was cut into 350 μm thick tissue slices with the use of a vibrating blade 
microtome. The slicing procedure took on average 45 to 60 minutes and yielded between 12 
and 17 slices per sample.  The first slice (non-cultured, control, time point 0 h) was 




Optimal culture conditions were determined by following a systematic evaluation of several 
media, supplements, oxygen tensions and the use of inserts in preliminary experiments at 
the inception of the study. These indicated better viability of the tissue slices in CMRL 
medium supplemented with 2.5 % human serum (type AB, Sigma-Aldrich), 25 mmol/L 
HEPES, 1 mmol/L sodium pyruvate, 3 nmol/L zinc sulfate, 1X insulin-transferrin-sodium 
selenite solution, 1X PenStrep, and 100 nmol/L diphenyl diselenide (antioxidant). Slices 
were cultured at 37 °C in a humidified incubator for at least 96 h. Slices were rested on an 
organotypic insert (Millipore, 0.4 μm pore size) placed in a 35 mm culture dish containing 
1.1 ml culture medium with a small volume (0.55 ml) of medium on top to prevent the 
tissue from drying out. Nine tumors were cultured under hyperoxic (41 % O2) conditions 
and three under both hyperoxic and atmospheric (21 % O2) conditions. Every 24 h, 
duplicate slices were harvested, embedded in paraffin, and processed for histology. The 
workflow for tissue slice preparation, culture and analysis is shown in Figure 4. 
 
 
Figure 4 - Schematic representation of the workflow, including preparation, culture, and 
analysis of precision-cut tissue slices of human PDAC. From Misra S et al. Ex vivo 
organotypic culture system of precision-cut slices of human pancreatic ductal 
adenocarcinoma. Sci Rep. 2019 Feb 14;9:2133. Copyright © 2019, Misra S et al. CC-BY. 
Hematoxylin and eosin (H&E) stained sections from the tissue slices were digitalized at 
20X magnification. The digital slides were used for histomorphological assessments, 
including evaluation of the histological grade of differentiation, and quantification of tissue 
viability and cell outgrowth based on manual annotations and numeric processing of the 
annotation data using R. Main readouts were (i) the percentage of the entire tissue slice area 
showing damage (necrosis, apoptosis) and (ii) the percentage of the total perimeter of the 
tissue slice that was covered by either cancerous or non-neoplastic cell outgrowth. 
Quantitations were averaged over duplicate slices for each culture and time point (0 h, 24 h, 
48 h, 72 h, and 96 h). Ultrastructural integrity was assessed by transmission electron 
microscopy in three cultures at 0 h, 24 h and 72 h. Immunohistochemical staining was 
performed using an automated immunostainer with a panel of markers to distinguish 
between epithelial, ductal/acinar, cancerous/non-neoplastic cell populations  (CK7, CK18, 
CK19, trypsin, CA19-9, maspin, P53, SMAD4); to identify stromal cells (vimentin, α-
SMA, D2-40, CD34), immune cell lineages (CD3, CD20, CD68), proliferating cells (Ki67); 
and to assess metabolic activity (pS6 mTOR pathway). Proliferative activity (Ki67-index) 
was assessed on all slices from seven cultures by manual annotation in hot-spots using 
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ImageJ (version 1.50i).  Expression of stromal and immune cell markers and pS6 in cancer 
cells was quantified by digital image analysis using QuPath (version 1.3).  
Comparisons of tissue viability, cell outgrowth, and proliferative activity between time 
points were performed using the Friedman test or Wilcoxon paired signed-rank test 
between matched cultures under hyperoxic and atmospheric O2 conditions. Dunn’s test was 
employed for multiple comparisons correction. A p-value of < 0.05 was considered 
statistically significant. Data analyses were performed using GraphPad Prism (version 6) 
and R (version 3.4.3). 
 
Work 3 (“Genome-wide Transcriptome Profiling of Ex-Vivo Precision-Cut Slices from 
Human Pancreatic Ductal Adenocarcinoma”) was a continuation study for the molecular 
characterization of the cultured tissue slices in Work 2. Hence, this was a retrospective 
study on tissue material from previously published tissue slice cultures of human PDAC. 
Criteria for inclusion were balanced grades of differentiation in the study series and 
availability of sufficient tissue material for analysis. Among duplicate slices, the one with 
higher tumor tissue content was selected. Five tissue slice cultures were included in the 
study, comprising two well differentiated, one moderately differentiated and two 
moderately to poorly differentiated carcinomas. For each culture, 0 h, 24 h, 48 h and 72 h 
time points were investigated. 
The corresponding formalin-fixed paraffin-embedded tissue slice blocks were sectioned 
(2 × 10 μm curls). Subsequently, total RNA was extracted and cDNA whole transcriptome 
sequencing libraries were prepared using the Takara Smarter total-RNA Seq kit V2 Pico 
Input Mammalian (Takara Bio Inc). Ribosomal cDNA sequences were cleaved in the 
process. Both extracted RNA and generated libraries were quantified using respective Qubit 
4.0 HS Assay Kits (Thermofisher Scientific). A total of twenty normalized libraries were 
sequenced using a NextSeq 500 Illumina system with High Output V2 Kit, generating a 
median of 40 million raw paired-end reads/sample. Processing and analysis of sequencing 
data were performed using the open source Chipster bioinformatic platform at IT Center for 
Science Finland (https://chipster.csc.fi). All sequences were quality-checked by FASTQC. 
Sequences were then aligned to Human Sapiens genome GRCh38.95 with TopHat2, 
assembled with Cufflinks and analyzed for differential gene expression using Cuffdiff. For 
the latter, differences in FPKM (Fragment Per Kilobase Million) values were considered 
significant when p-values were equal or less than 0.05. Finally, to predict for possible 
molecular functional and gene-pathway interactions, the significant differentially expressed 
genes were queried for over-represented pathways in the ConsensusPathDB-human 
database (Max Planck Institute, http://cpdb.molgen.mpg.de), which integrates interaction 
networks from 32 public databases, and the results assessed for statistical significance using 
hypergeometric distribution probability test. 
 
Work 4 (“Selenium Compounds Exert Tumor-specific Cytotoxicity on Pancreatic Cancer 
and Suppress DDR2 and CEMIP in Human Organotypic Cultures”) was a prospective 
preclinical experimental study. PDAC tumor samples from 9 chemonaïve patients operated 
at Karolinska University Hospital were cultured for 72 h at atmospheric (21 %) O2 tension 
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according to the method previously established in Work 2, except for the addition of 
diphenyl diselenide. At 24 h, tissue slices were exposed during subsequent 48 h of culture 
by replacing the culture medium with fresh medium spiked with the following drugs at 
various concentrations: sodium selenite (Se) at 5 µM, 15 µM and 30 µM; 
methylselenocysteine (MSC) at 100 µM, 250 µM and 500 µM (single agent) and in 
combination with 200 µM indole-3-pyruvic acid (IPA); and gemcitabine 1 µM and IPA 200 
µM alone. Cultured but untreated slices were used as controls (‘Control 72 h’). The 
different treatment conditions were tested in duplicate slices. When removed from culture, 
slices were fixed in formalin, embedded in paraffin, and processed for histology. H&E 
sections were evaluated to confirm the presence of PDAC and to assess the grade of 
differentiation. Immunohistochemistry for CK19 was performed on all slices from one 
culture with extensive infiltrate of a poorly differentiated carcinoma to demarcate the tumor 
regions for subsequent digital image analysis. All histological slides were digitalized at 20X 
magnification. Histomorphological assessments were performed on whole slide images 
using QuPath (version 0.2), based on manual annotations or for one culture digital image 
analysis. 
As our previous work 3 revealed during culture the progressive outgrowth of cancer cells 
along the surface of the tissue slices, this rather than the total tumor content (within the 
slice) was primarily assessed. The cancer cell outgrowth was manually annotated on H&E-
stained digital slide images (n = 109), using different labels for the various cell 
morphologies: flat/attenuated, cubic, cylindrical, clear, swollen and necro-apoptotic. These 
were finally simplified and combined into two morphological categories: “viable” 
(comprising flat, cubic, cylindrical, and clear) and (severely) “damaged” (comprising 
swollen and necro-apoptotic). These two categories were used for downstream statistical 
analyses and for the morphological assessment within the slice of two tumors that did not 
show outgrowth, corresponding to a poorly differentiated carcinoma with solid growth 
pattern and a moderately differentiated carcinoma with dispersed mode of invasion between 
pancreatic lobuli in a background of chronic pancreatitis. 
Based on the morphological assessments described above, the following readouts were 
considered as most reliable for the evaluation of drug response  in the tissue slices: the 
percentages of “viable” and  “damaged” tumor, the length of cancer cell outgrowth as 
percentage of the total slice perimeter, and a custom metric, termed tumor viability index, 
defined as the sum of products of the outgrowth lengths and viability weights, according to 
the formula “Σi=viable, damaged(% outgrowth lengthi * weighti)”, where weight = 3 for “viable” 
and = 1 for “damaged” cancerous outgrowth, respectively.  
Quantitative data derived from the annotations were averaged over duplicate slices and 
processed using R (version 3.6.3). As Shapiro’s tests indicated non-normally distributed 
values, non-parametric Wilcoxon tests were used for matched comparison between cultured 
but untreated control slices and the different treatment conditions, with Benjamini & 
Hochberg correction for multiple testing. An adjusted p-value < 0.05 was considered 
statistically significant. 
Transcriptomic analysis was performed for seven cultures with similar methods as 
described above in Work 3 and for the following conditions: IPA 200 µM, Gemcitabine 
1 µM, Se 15 µM, MSC 100 µM, and MSC 100 + IPA 200 µM. Briefly, total RNA was 
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extracted from formalin-fixed paraffin-embedded sections and used to prepare cDNA 
libraries. After depletion of ribosomal cDNA, libraries were sequenced using NextSeq. 500 
Illumina system, which generated a median of 25 million raw paired-end reads per sample. 
Processing of sequencing data and differential gene expression analysis using DESeq2 
Bioconductor package were performed through Chipster bioinformatic interface at IT Center 
for Science Finland. Differences in gene expression with adjusted p-value ≤ 0.05 and 
log2fold change of +1 or -1 were initially considered statistically significant. To identify the 
most significant differentially expressed genes, results were subsequently filtered using a 
cut-off p-value of 0.000,1. Heatmaps and dendrograms of RNA expression profiles were 
generated with Chipster, and volcano plots using the open-source Galaxy platform for 
computational research (https://galaxyproject.org). 
Ethical considerations: 
The research in Work 1 was approved by the Regional Ethical Review Board, Stockholm, 
with diary number 2015/259-31/2. Signed consent from patients was not required due to the 
retrospective nature of the study and the commonly poor prognosis of the analyzed tumor 
types. 
The research in Works 2-4 was approved by the Regional Ethical Review Board, 
Stockholm, diary number 2012/1657-31/4. All patients who participated in the studies 
received oral and written information and they voluntarily signed the consent form 
regarding inclusion, tissue sampling, culturing, analysis, and collection of associated 
clinicopathological data. Approval for sample collection (Bbk number 1039) was obtained 
from Stockholms Medicinska Biobank. In February 2019, an amendment was approved by 
Etikprövningsmyndigheten (diary number 2019-00788) that gave permission to use the 
patient’s (autologous) serum to further improve culture conditions, to include 
preoperatively treated (downstaged) PDAC and all types of periampullary cancer (including 
neuroendocrine tumors) as well as to send tissue samples for analysis in laboratories abroad 
after signing of a Material Transfer Agreement. In this amendment, an updated patient 
information sheet compliant with EU’s GDPR regulation was also included. 
Participation in the studies did not entail any risks to the participant patients, because all 
investigations were performed exclusively on a small amount of surplus tumor tissue that was 
neither required for diagnostics nor any other medical care-related purposes. Participation in 
the study did not entail any possible complications for the participant patients. 
There was no direct benefit for the individual patient from taking part in this research. The 
overall results of the studies may, however, contribute to improve treatment of patients with 
pancreatic cancer in the future, for example by selecting more effective drugs with the ex-
vivo tissue slice culture system. 
The risk of damage of personal integrity for participant patients was minimized by 
pseudonymizing all data and storing the key on a locked computer at the Department of 
Clinical Pathology and Cytology at Karolinska University Hospital, Huddinge. 
Being able to test ex-vivo the individual patient’s tumor with different candidate drugs is 
highly relevant as it has the potential to contribute to the implementation of precision 
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medicine in clinical practice, by providing guidance for the postoperative treatment. These 





Work 1 (“Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System 
Improves Diagnosis and Prognostic Stratification”): 
After data pre-processing (analysis of missing data, removal of tumor samples with a high 
amount of missing data and imputation of missing data in the remaining), the final series for 
analysis comprised 264 core needle biopsies and 145 resection specimens of ampullary 
carcinoma (n = 24), pancreatic ductal adenocarcinoma (PDAC; n = 139), distal bile duct 
cancer (n = 7), gallbladder cancer (n = 37), perihilar cholangiocarcinoma (n = 27), 
intrahepatic cholangiocarcinoma (n = 97), and hepatocellular carcinoma (n = 78).  
Principal component analysis showed no clustering of pancreatobiliary tumors according to 
the immunohistochemical marker panel or the type of probe (biopsy/resection), disregarding 
these as potential confounding factors. Unsupervised hierarchical cluster analysis identified 
four main tumor groups: extrahepatic pancreatobiliary, intestinal, intrahepatic 
cholangiocarcinoma, and hepatocellular carcinoma. The intestinal group (n = 24) included 8 
PDACs, 7 ampullary carcinomas and 4 gallbladder cancers, while 27 intrahepatic 
cholangiocarcinomas clustered in the extrahepatic pancreatobiliary group. Most PDACs (116 
out of 139) clustered in the extrahepatic pancreatobiliary group. The main tumor clusters 
were further confirmed by using a different clustering technique based on complex network 
(Figure 5).  
 
Figure 5 - Clustering of adenocarcinomas of the pancreatobiliary system according to 
immunohistochemical expression data. Adapted from Fernández Moro C et al. 
Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves 
Diagnosis and Prognostic Stratification. PloS One. 2016;11:e0166067. Copyright © 2016 
Fernández Moro C et al. CC-BY. 
Differential expression analysis revealed the markers with significantly different expression 
between the various groups (from hierarchical clustering): extrahepatic pancreatobiliary vs 
intestinal, extrahepatic pancreatobiliary vs intrahepatic cholangiocarcinoma, and intrahepatic 
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cholangiocarcinoma vs hepatocellular carcinoma. Comparative immunohistograms were 
generated to visualize differences in expression between the immunohistochemical tumor 
groups, for the markers that were selected by differential expression analysis, using a cutpoint 
of 10 % for the extent of positive staining in tumor cells (Figure 6). Complex network 
visualizations effectively depicted the expression levels of each marker for every individual 
tumor in the immunohistochemical clusters. These were internally validated by a different 
approach using machine learning models. Robustness of discrimination between the 
immunohistochemical tumor groups was confirmed for the full set of (n = 27) markers 
(average ROC area value about 0.96) and using only the significant markers according to 
differential expression (average ROC area value 0.95). A simplified immunohistochemical 
panel of eight makers (CK19, CK20, MUC2, MUC5AC, CA19-9, monoclonal CEA, CA125 
and SMAD4) was finally proposed as a guide for the diagnosis of the immunohistochemical 
tumor types. 
 
Figure 6 – Comparative immunohistograms depicting the distinguishing markers between the 
immunohistochemical tumor groups. Adapted from Fernández Moro C et al. 
Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves 
Diagnosis and Prognostic Stratification. PloS One. 2016;11:e0166067. Copyright © 2016 
Fernández Moro C et al. CC-BY. 
Survival analysis was performed for 86 patients who had undergone surgical resection of the 
primary tumor. The general short overall survival (OS) of non-resected patients (only 
diagnostic biopsy, median OS = 6 months) precluded a meaningful survival analysis in this 
group. In the resected group, median OS was 24 months for the extrahepatic pancreatobiliary, 
54 months for the intestinal, and 109 months for the intrahepatic cholangiocarcinoma 
immunohistochemical types. Overall, Cox proportional hazards models including the 
immunohistochemical tumor classification were statistically significant both in univariate 
(p < 0.001) and multivariate (p = 0.001) analyses. In particular, the intestinal type (p = 0.014, 
adjusted HR = 0.19, 95 % CI = 0.05 ± 0.72), pT4 (p = 0.002), and pN0 (p = 0.045) were 
independent predictors of OS. In contrast, Cox proportional hazards models including the 
anatomically-based tumor classification were statistically significant on multivariate analysis 
(p = 0.005), but only pT4 (p = 0.035) and pN0 (p = 0.020), and not the anatomical tumor 
location, were independent predictors of OS. When restricting the analysis to the extrahepatic 
pancreatobiliary and intestinal immunohistochemical types, the latter was consistently 
associated with a more favorable OS (univariate: p = 0.025, crude HR = 0.33, 95 % CI = 




Figure 7 - Kaplan-Meier plot for overall survival by immunohistochemical tumor types. 
Adapted from Fernández Moro C et al. Immunohistochemical Typing of Adenocarcinomas of 
the Pancreatobiliary System Improves Diagnosis and Prognostic Stratification. PloS One. 
2016;11:e0166067. Copyright © 2016 Fernández Moro C et al. CC-BY. 
 
Work 2 (“Ex-Vivo Organotypic Culture System of Precision-Cut Slices of Human Pancreatic 
Ductal Adenocarcinoma”): 
The procedure yielded a median of 14 (range: 12-17) tissue slices, 350 μm in thickness per 
tumor sample. The median area of tissue slices was 31.9 mm2 (range: 20.1–57.9 mm2). 
Light microscopic evaluation revealed overall good morphological preservation of the tissue 
slices during the entire culture period. Necrotic and apoptotic cell death were observed in 
discrete areas within the first 24 h of culture, while no further tissue damage was observed 
during subsequent 72 h (Figure 8). Spatial distribution of non-viable tissue areas showed that 
these were highest in the peripheral zone of the tissue slices, followed by the intermediate 
one. 
Examination by transmission electron microscopy showed that at 72 h, overall, most cell 
populations, including the cancer cells and cancer associated fibroblasts, maintained 
ultrastructural integrity. Damage was mainly limited to the endothelial cells and the presence 




Figure 8 – Analysis of tissue viability in precision-cut PDAC slices. Red annotation areas in 
central panels indicate non-viable tissue. Photomicrographs, H&E staining. Adapted from 
Misra S et al. Ex vivo organotypic culture system of precision-cut slices of human pancreatic 
ductal adenocarcinoma. Sci Rep. 2019 Feb 14;9:2133. Copyright © 2019, Misra S et al. CC-
BY. 
Each of the cultured adenocarcinomas retained its characteristic histological and cytological 
features and grade of differentiation (well, moderate to poor, poor non-gland forming) 
throughout the culture period (0-96 h) (Figure 9). 
 
Figure 9 - Tumor histomorphology and grade of differentiation in the tissue slices. H&E 
staining. From Misra S et al. Ex vivo organotypic culture system of precision-cut slices of 
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human pancreatic ductal adenocarcinoma. Sci Rep. 2019 Feb 14;9:2133. Copyright © 2019, 
Misra S et al. CC-BY. 
Histological examination revealed during culture the gradual outgrowth of cancer cells and 
non-neoplastic cells on the surface of the tissue slices (Figure 10). The cancerous cell 
outgrowth was composed of atypical cells. While the non-neoplastic cell outgrowth consisted 
mainly of cells that were fairly flat at the beginning of the culture but became progressively 
taller and cylindrical towards the end, an observation that indicated cellular maturation. Both 
the cancerous and non-neoplastic cell outgrowths were positive for CK19 and negative for 
vimentin and trypsin, confirming that these were cancer cells and ductal epithelial cells, 
respectively. The cancerous phenotype was confirmed by P53 overexpression or SMAD4 
negativity. Quantitation data showed that the cancerous cell outgrowth was more extensive 
than the non-neoplastic one. All together, these findings suggest the involvement of active 
tissue repair and proliferation in the cultured tissue slices. 
 
Figure 10 - Cancerous (red arrows and areas) and non-neoplastic (black arrows and areas) 
cell outgrowths. Top left: H&E staining. Bottom left: immunohistochemistry. Adapted from 
Misra S et al. Ex vivo organotypic culture system of precision-cut slices of human pancreatic 
ductal adenocarcinoma. Sci Rep. 2019 Feb 14;9:2133. Copyright © 2019, Misra S et al. CC-
BY. 
Moreover, cancer cell outgrowth maintained the characteristic cytomorphological features 
related to the grade of differentiation of the tumor within the tissue slices (Figure 11). Well 
differentiated tumors formed single-layered outgrowths composed of cells with mildly 
atypical, polarized nuclei. Moderately differentiated tumors formed outgrowths that showed a 
variable degree of (pseudo)stratification and were composed of overtly atypical cells with 
nuclear pleomorphism and loss of polarization. Non-gland forming, poorly differentiated 
carcinomas developed patchy outgrowths of highly atypical cells that focally tended to detach 
from the slice surface. Quantitatively, the extent of the cell outgrowth relative to the 
perimeter of the tissue slice increased with better differentiation grade. At 96 h, the median 
percentage of the slice perimeter covered by cancer cell outgrowth was 71.2 % (range 20.0–
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81.9 %) in well differentiated tumors, 43.9 % (range 39.6–90 %) in moderate to poorly 
differentiated ones, and 27.3 % (range 12.3–39.0 %) in non-gland forming, poorly 
differentiated carcinomas. 
 
Figure 11 - Cancerous cell outgrowth and grade of tumor differentiation. Top: H&E 
staining. From Misra S et al. Ex vivo organotypic culture system of precision-cut slices of 
human pancreatic ductal adenocarcinoma. Sci Rep. 2019 Feb 14;9:2133. Copyright © 2019, 
Misra S et al. CC-BY. 
Although not quantified, it was noticed that in better differentiated tumors the total tumor cell 
content tended to decrease gradually within the slice during culture time, while it became 
prominent (as outgrowth) on the slice surface. 
The cancer cells continued proliferating (as assessed by Ki67 index) during culture, both 
within the slice and on the surface (Figure 12). Overall, proliferation was higher within the 
slice and in poorly differentiated tumors. Over time, proliferation remained steady in poorly 




Figure 12 - Cancer cell proliferation. From Misra S et al. Ex vivo organotypic culture system 
of precision-cut slices of human pancreatic ductal adenocarcinoma. Sci Rep. 2019 Feb 
14;9:2133. Copyright © 2019, Misra S et al. CC-BY. 
As the mTOR pathway is a central regulator of cellular metabolism and growth, 
phosphorylation of ribosomal protein S6, downstream of mTOR, was used as a marker of 
metabolic activity in the tissue slices. The cancer and stroma cells were positive for pS6. The 
average levels of pS6 in the cancer cells were higher at 24 h when compared to the control, 
non-cultured slices, and remained stable at later time points. 
Following successful preservation of tissue viability under hyperoxic condition (41 % O2 
level), we investigated slice culturing at atmospheric condition, 21 % O2 level. Morphological 
analyses did not reveal quantitative differences in tissue viability, cell outgrowth, 
proliferation, or metabolic activity between paired tissue slices cultured under hyperoxic or 




Figure 13 - Tissue viability, cell outgrowth, proliferation and metabolic activity of matched 
tissue slices cultured under hyperoxic (41 % O2) and atmospheric (21 % O2) conditions. Top-
left, H&E staining. Adapted from Misra S et al. Ex vivo organotypic culture system of 
precision-cut slices of human pancreatic ductal adenocarcinoma. Sci Rep. 2019 Feb 
14;9:2133. Copyright © 2019, Misra S et al. CC-BY. 
As the stroma is a key component of the microenvironment, both the cancer-associated and 
the residual pancreatic stroma were characterized by immunohistochemistry at 0 and 72 h 
(Figure 14). At both time points, cancer-associated stroma was positive for vimentin, α-SMA 
and D2-40, while it was negative for CD34. In contrast, residual pancreatic stroma was 
positive for vimentin, CD34, and partially for α-SMA, while D2-40 was negative or minimal. 




Figure 14 - Immunohistochemical characterization of stroma and immune cells in cultured 
tissue slices. In cancer-associated stroma: black arrows - cancer associated fibroblasts (α-
SMA, D2-40) and immune cells (CD3, CD68), yellow arrows - cancer cells, blue arrow – 
smooth muscle cells. In residual pancreatic stroma: yellow arrows – pancreatic acini and 
ducts, blue arrows – islet of Langerhans (CK18) and smooth muscle cells (Cald), black 
arrows – lobular stroma (α-SMA, D2-40) and immune cells (CD3, CD68). From Misra S et 
al. Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal 
adenocarcinoma. Sci Rep. 2019 Feb 14;9:2133. Copyright © 2019, Misra S et al. CC-BY. 
 
Work 3 (“Genome-wide Transcriptome Profiling of Ex-Vivo Precision-Cut Slices from 
Human Pancreatic Ductal Adenocarcinoma”): 
On histomorphology, four out of five analyzed cultures showed, based on data from Work 2, 
minimal (range 0-6 %) and one mild to moderate (0-18 %) tissue damage, between 0 h 





Figure 15 - Morphological viability in representative tissue slice cultures. Red areas (slice 
diagrams) and arrows (photomicrographs, H&E staining) indicate non-viable tissue regions. 
Adapted from Ghaderi M et al. Genome-wide Transcriptome Profiling of Ex-Vivo Precision-
Cut Slices from Human Pancreatic Ductal Adenocarcinoma. Scientific Reports. 2020 Jun 
3;10:9070. Copyright © 2020, Ghaderi M et al. CC-BY. 
 
A total of 58,713 genes (coding and non-coding) and 206,487 gene transcripts were analyzed 
for differences in expression levels between 24 h intervals (24-72 h) and baseline (0 h). Only 
a limited number of genes were significantly upregulated (median of 12, 10 and 15 genes) or 
downregulated (median of 15, 12 and 25 genes) during culture (at 24, 48 and 72 h, 
respectively), as compared to baseline. No statistically significant differences in transcript 
isoform expression were detected at any time point. 
The list of suggested top three pathways that were significantly overrepresented for each 
culture, the three time points together (24-72 h), is shown below (Table 1). Cathepsin L 
(CTSL) was upregulated in all cultures, which together with varying up- or downregulation 
of matrix metalloproteinase, collagen and laminin transcripts suggested remodeling of the 
extracellular matrix.  
One culture (OT9) with morphologically increased areas of tissue damage showed 
upregulation of PTGS2, IGFBP1, PMAIP1 and VEGFA genes, which suggests activation of 
apoptosis via HIF-1/quercetin/NF-ĸB/AP-1 interaction pathways (138–141). In this culture, 
several mitochondrial transcripts were also downregulated at 72 h, suggesting a drop in 
oxidative phosphorylation by downregulation of NADH dehydrogenase (MT-ND1-6) and 
electron transport chain (MT-CO1-2 and -CYB) activity. 
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Table 1 - Top 3 significantly suggested pathways (all time points together, 24-72 h) for every 
culture. From Ghaderi M et al. Genome-wide Transcriptome Profiling of Ex-Vivo Precision-
Cut Slices from Human Pancreatic Ductal Adenocarcinoma. Scientific Reports. 2020 Jun 




Work 4 (“Selenium Compounds Exert Tumor-specific Cytotoxicity on Pancreatic Cancer 
and Suppress DDR2 and CEMIP in Human Organotypic Cultures”): 
The case series comprised five moderately, two moderately to poorly, and two poorly 
differentiated carcinomas. Seven out of nine tumors showed a prominent cancer cell 
outgrowth during culture. This presented several distinct histomorphological appearances 
(‘flat’/attenuated, ‘cubic’, ‘cylindrical’) as well as varying degrees of morphological changes 
that are associated with cellular stress and damage (‘clear’ > ‘swollen’ > ‘necro-apoptotic’) 
(Figure 16). As described above in Methods, the former (‘flat’, ‘cubic’, ‘cylindrical’ and 
‘clear’), which were most abundant in untreated slices, were combined as ‘viable’ for 
downstream analysis; while the latter (‘swollen’ and ‘necro-apoptotic’), which were most 
prominent in treated slices, were grouped as ‘damaged’. The other two tumors that did not 





Figure 16 – Representative photomicrographs illustrating the varying morphological 
appearances of the cancer cells (top) as outgrowth and (bottom) within the slice, H&E 
staining. 
 
Median overall percentages of tumor (cancer) cell viability, all concentrations together, were 
82 %, 9 %, 39 % and 47 % in control, Se and MSC alone or in combination with IPA, 
respectively. Major tumor responses, defined as a percentage of ‘damaged’ cancer cells > 
90 %, closely corresponding to Evans’ (142) tumor regression grades III-IV, were observed 
for several treatment conditions: Se 30 µM (in n = 7 cultures), Se 15 µM (n = 5), MSC 
100 µM, MSC 250-500 µM ± IPA 200 µM (n = 3 each) and MSC 100 µM + IPA 200 µM (n 




Figure 17 - Tumor viability for every culture and treatment condition. 
Se 5-30 µM and MSC 100-500 µM ± IPA 200 µM treatments showed significant reductions 
in tumor cell viability as compared to matched untreated slices (Control 72 h) (Figure 18). 
The adjusted p-values ranged between 0.014 and 0.019 and effect sizes between 0.84 and 
0.89 (large). Median tumor cell viability ranged from 52.4 % to 1.9 % for Se 5-30 µM, from 
52.3 % to 25.1 % for MSC 100-500 µM and from 56.5 % to 30.2 % for MSC 100-500 µM + 





Figure 18 - Differences in tumor viability as compared to untreated controls for every 
condition. 
Median percentages of cancerous outgrowth length, all concentrations together, were 56 %, 
24 %, 60 % and 42 % for control, Se and MSC alone or in combination with IPA, 
respectively. These showed a decreasing trend with selenium treatments as compared to 




Figure 19 - Differences in cancerous outgrowth length as compared to untreated controls for 
every condition. 
Median values of tumor viability index (sum of products of the outgrowth lengths and 
viability weights), all concentrations together, were 157, 31, 122, and 96 in control, Se and 
MSC alone or in combination with IPA, respectively.   
Se 5-30 µM, MSC 500 µM and MSC 100-500 µM + IPA 200 µM treatments showed 
significant reductions in tumor viability index (Figure 20). Adjusted p-values were 0.049 and 
effect sizes 0.90 (large) each. Median tumor viability index ranged from 117.9 to 14.4 for Se 





Figure 20 - Differences in tumor viability index as compared to untreated controls for every 
condition. 
 
Visual histomorphological assessment showed no overt signs of treatment-related damage of 




Figure 21 - Representative photomicrographs of the stroma in the tissue slices, H&E 
staining. Green arrows: preserved stroma. Blue arrows: remnants of pancreatic parenchyma. 
Yellow arrows: immune cells. Scale bar: 100 μm. 
 
Transcriptomic analysis of Se 15 µM as compared to (untreated) control slices showed 
upregulation of 1099 (2.1 %) and downregulation of 738 (1.4 %) out of 53594 gene 
transcripts. Subsequent filtering by a p-value cutpoint of 0.000,1 resulted in a list of 38 highly 
differentially expressed genes. Specifically, CEMIP, PLOD2, DDR2 and P4HA1, genes 
involved in extracellular matrix remodeling, cancer growth and metastatic potential, were 
significantly downregulated, while the cell death-inducing genes ATF3 and ACHE were 
significantly upregulated in Se 15 µM treated slices (Figure 22). The top three and most 
significant associated pathways were the 'Attenuation phase of the heat shock transcriptional 
response', 'Collagen formation', and 'Heat shock factor 1 (HSF1)-dependent transactivation'. 
MSC 100 µM treated slices showed significant upregulation of CRYAB and HSB8, which 





Figure 22 – Heatmap and volcano plot of highly differentially expressed genes between Se 15 µM 






Work 1 (“Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System 
Improves Diagnosis and Prognostic Stratification”) developed an immunohistochemical 
classification that integrated and simplified the anatomy-based (WHO) (137) classification of 
adenocarcinomas of the pancreatobiliary system: pancreatic ductal adenocarcinoma, 
ampullary carcinoma, distal bile duct cancer, gallbladder cancer, perihilar 
cholangiocarcinoma, and intrahepatic cholangiocarcinoma.  It introduced three main 
immunohistochemical types - extrahepatic pancreatobiliary, intestinal, and intrahepatic 
cholangiocarcinoma - along with their respective characteristic and discriminant markers and 
showed that the intestinal type was associated with a significantly better survival than the 
pancreatobiliary type, both in univariate analysis and after adjusting for tumor stage (pT) and 
lymph node status (pN). 
This work contributes further evidence to a number of studies (87,88) that emphasize the 
histological type (pancreatobiliary vs intestinal) rather than anatomical localization as a 
determinant factor for overall survival after surgical resection of the primary tumor. In the 
present series, 8 out of 139 PDAC (6 %) were classified as intestinal type, a slightly lower 
proportion than reported in previous studies, e.g. Albores-Saavedra et al. 11 out of 110 
(10 %) (83) and Bronsert et al. 11 out of 126 (9 %) (88). In previous studies, the 
pancreatobiliary and intestinal tumor types were categorized mostly based on H&E staining 
(83), and it was recognized that a fraction of tumors are difficult to classify due to mixed or 
intermediate histological features (84,88). Similarly, intrahepatic cholangiocarcinoma can be 
very difficult to distinguish on H&E staining from metastatic adenocarcinoma. Still, 36 out of 
the 409 tumors in the study cohort could not be meaningfully classified by the unsupervised 
clustering approach, which is a limitation of the study and may indicate different or 
intermediate immunohistochemical subtypes. The comprehensive immunohistochemical 
panels and discriminant markers presented in the study may prove useful to improving the 
differential diagnosis of pancreatobiliary vs intestinal and intrahepatic cholangiocarcinoma 
tumor types. 
Work 2 (“Ex-Vivo Organotypic Culture System of Precision-Cut Slices of Human Pancreatic 
Ductal Adenocarcinoma”) presents a model that is unique in allowing culturing of entire 
pancreatic cancer tissue, i.e., the cancer cells and their native microenvironment, with  good 
preservation of tissue viability and structural integrity during at least 96 h. Importantly, the 
cancer cells retain their grade of differentiation and morphological phenotypes, and continue 
proliferating, while the stroma remains intact. Cancer cells form a progressively extending 
outgrowth on the surface of the tissue slices, a phenomenon reminiscent of “wound healing”.  
Results were comparable when culturing under hyperoxic (41 % O2) and atmospheric (21 % 
O2) conditions, suggesting that tissue oxygenation was not a limiting factor. 
The conventional set-up for drug testing and experimental cancer biology relies significantly 
on the use of cell lines and genetically engineered or xenograft-based animal models. Even if 
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these models recapitulate some of the features of human pancreatic cancer, there are 
important limitations, mainly the lack of the native tumor microenvironment and the use of 
hosts from different species that may be immunocompromised. For decades, tissue slice 
cultures have been used to study physiology, metabolism, and toxicity (96). More recently, 
precision-cut tissue slices have been employed to investigate drug effects in various tumor 
types, such as breast cancer (100,109), glioblastoma (101,110), and lung cancer (114). When 
it comes to the pancreas, most previous research has focused on acinar and neuroendocrine 
cell physiology (105), transfection efficiency for viral-vector-mediated gene therapy (103), 
pancreatic stellate cell activation (104), and PDAC immunotherapy (108). Some limitations 
of the slice models are that they are not currently adapted for high-throughput analysis and 
long-term (weeks to months) culture and that interslice variation makes quantitation and 
comparison of readouts difficult. The presented model, being a close surrogate of the parent 
tumor, represents a significant step forward in the search for models that are clinically 
relevant with a view to precision medicine and tumor biology investigations, as it factors in 
the tumor microenvironment, in particular the cancer stroma and the immune cell 
populations. 
In Work 3 (“Genome-wide Transcriptome Profiling of Ex-Vivo Precision-Cut Slices from 
Human Pancreatic Ductal Adenocarcinoma”) five tissue slice cultures from Work 2 were 
characterized at the transcriptome level. Differential expression and pathway 
overrepresentation analysis revealed that, overall, only a limited number of genes were 
significantly up- or downregulated at 24 h intervals (24 to 72 h) as compared to baseline (0 h, 
non-cultured). One culture with increased areas of tissue damage on histomorphological 
assessment showed upregulation of VEGFA and PTGS2, a finding that highly likely reflects 
activation of HIF-1-triggered cell apoptosis. 
Davies et al. (102)  performed thorough characterizations of precision-cut tissue slices from 
different human and animal model derived tumors and found that hypoxia and stress of the 
tissue slices were associated with HIF-1α overexpression on immunohistochemistry. In the 
present work, VEGFA and HIF-1 pathways were upregulated specifically in a culture with 
increased tissue damage, which is in line with the observation by Davies et al. A limitation of 
the study is that bulk transcriptomic analysis was performed for the entire slice tissue, while 
microdissection was not performed to enrich specifically for tumor content. The study results 
support that transcriptomic analysis is a valuable complement to morphology for the 
evaluation of precision-cut tissue slice cultures. 
In Work 4 (“Selenium Compounds Exert Tumor-specific Cytotoxicity on Pancreatic Cancer 
and Suppress DDR2 and CEMIP in Human Organotypic Cultures”) the previously 
established tissue slice model (in Works 2 and 3) was used to investigate cytotoxic effects in 
human PDAC using a panel of two selenium compounds (selenite and methylselenocystein) 
at various concentrations. Morphology based quantitations showed pronounced decreases in 
tumor viability after 48 h of exposure to Se at doses of 15 µM and 30 µM. These were 
associated at the transcriptome level by upregulation of the cell death-inducing genes ATF3 
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(143) and ACHE (144), and downregulation of CEMIP (hyaluronan degradation) (145), 
PLOD2 (146), DDR2 (147) and P4HA1 (148), genes involved in extracellular matrix 
remodeling, cancer growth and metastatic potential. 
During the past decade, a growing number of studies have used ex-vivo slice cultures to 
address key questions related to oncogenic signaling pathways (97), intratumoral 
heterogeneity (114), drug responses (109,112), and oncoimmunology (108,110). The present 
study further supports that tissue slice cultures are a suitable model for drug sensitivity testing 
in samples of surgically resected human PDAC. 
The marked responses to Se 15-30 µM observed in the present study are in line with the 
cytotoxic effects reported in previous experiments in cell lines. Moreover, the doses in the 
range 15-30 µM are below the maximum tolerated dose of selenium in humans, as previously 
reported in a phase I clinical trial by our group (136). 
The study has some limitations. Further readouts associated with response to treatment such 
as total tumor cell content, apoptotic/cell death fraction and functional assays of tumor cell 
viability, which may be suitable for the assessment of cancer types that form large, compact 
masses, could not be applied due to the intrinsic features of PDAC: the presence of a 
prominent stroma, a lower tumor cell density, and a more disperse tumor growth, commonly 
intermixed with remnants of non-neoplastic pancreatic parenchyma. Time-lapse from drug 
exposure to slice harvesting may also impact the possibility of read-out detection, e.g., 
apoptotic markers (M30, activated caspase 3) could no longer be detected in preliminary 
experiments in a fraction of severely damaged/necrotic cancer cells, likely due to protein 
degradation at advanced phases of cell death. The reasons above led us conclude that a 
thorough assessment of cancer cell morphology was the most reliable and consistent readout 
for evaluation of drug response-associated cell damage in precision-cut tissue slices of human 
PDAC after selenium treatment. Finally, bulk RNA analysis, i.e., with inclusion of the tumor 














Work 1 (“Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System 
Improves Diagnosis and Prognostic Stratification”): 
Integrative immunohistochemical classification of adenocarcinomas of the pancreatobiliary 
system revealed three main immunohistochemical types: extrahepatic pancreatobiliary, 
intestinal, and intrahepatic cholangiocarcinoma and their characteristic and discriminant 
markers. 
Independent of anatomic location, the prognostically more favorable intestinal type can be 
distinguished from the more aggressive pancreatobiliary type. 
The characteristic immunohistochemical profile of intrahepatic cholangiocarcinoma 
positively supports its pathological diagnosis, which is commonly regarded as a diagnosis of 
exclusion (of metastatic adenocarcinoma). 
Work 2 (“Ex-Vivo Organotypic Culture System of Precision-Cut Slices of Human Pancreatic 
Ductal Adenocarcinoma”): 
Ex-vivo culture of precision-cut tissue slices enables the preservation of pancreatic cancer 
tissue in its entirety for at least 96 h and cancer cells retain their grade of differentiation, 
proliferation, and metabolic activity. The tumor microenvironment is preserved, including 
cancer-associated stroma and immune cell populations. 
Cultures of precision-cut PDAC slices provide a close approximation of the in-situ tumor in 
the patient. As such, they may constitute an unparalleled, short-term, high-content model for 
drug sensitivity testing and for the analysis of the complex interactions between cancer cells 
and their microenvironment. 
Work 3 (“Genome-wide Transcriptome Profiling of Ex-Vivo Precision-Cut Slices from 
Human Pancreatic Ductal Adenocarcinoma”): 
Genome-wide transcriptome analysis supports that ex-vivo cultured tissue slices of PDAC 
may be a representative model of the tumor tissue in-vivo, also at the molecular level. 
Transcriptome analysis was found to be a valuable complement to morphology for the 
evaluation of ex-vivo cultured tissue slices. 
Work 4 (“Selenium Compounds Exert Tumor-specific Cytotoxicity on Pancreatic Cancer 
and Suppress DDR2 and CEMIP in Human Organotypic Cultures”): 
Redox-active selenium compounds are promising candidate chemotherapeutic agents for the 





This ex-vivo model is relatively inexpensive, gives results within days and helps reducing 
animal experiments. 
Precision-cut tissue slice cultures of tumor samples from surgical specimens are a novel, 
promising tool for drug sensitivity testing. They enable a wide range of applications spanning 
from drug discovery to personalized cancer medicine in which a panel of drugs may be tested 







8 POINTS OF PERSPECTIVE 
 
Pancreatic cancer is currently the 4th leading cause of cancer-related death in the West. As it 
is projected to rank 2nd by 2030, it can be regarded a medical emergency. Despite advances 
in surgery and modest survival improvements with current chemotherapies, a breakthrough 
that dramatically improves survival is still awaited. 
PDAC is currently recognized as a (histomorphologically, immunohistochemically, and 
molecularly) heterogeneous disease, and therapeutically actionable subtypes are beginning 
to emerge. It is foreseeable that novel subtypes and classification schemes will be unveiled 
in the ongoing quest for precision and personalized medicine for patients with PDAC (149). 
It is conceivable that patients with tumors of the less aggressive intestinal type may benefit 
from tailored oncological treatment, e.g., more in line with colorectal cancer, and the 
possibility of resection of liver metastases. Future clinical trials would benefit from 
stratifying patients according to established PDAC subtypes. 
Tissue slice models may constitute a state-of-the-art tool for drug sensitivity testing and the 
implementation of personalized cancer medicine. To fully unfold their potential for oncology 
and tumor biology applications, further optimizations would be valuable, such as: 
 Improvements in tissue viability to consistently render the entire slice volume 
available for morphological and molecular assessments, investigations of tumor-
microenvironment interactions and experimental manipulations (anticancer drugs, 
pathway inhibitors and agonists). 
 Increase culture time with comparable viability, to enable experimental manipulations 
and assessment of temporal effects in the order of 7-10 days. 
 Establish an array of robust, correlated readouts at multiple levels (morphology-based 
labellings, genome/transcriptome/proteome, functional assays on the supernatants) to 
systematically assess the tissue slices. 
 Develop tailored digital image analysis pipelines for the automated and unbiased 
quantitation of labelled targets in the cancerous, stromal and immune cell populations 
and for the assessment of the spatial relations between them. 
 Machine learning/AI techniques may prove useful to analyze and integrate the 
multidimensional readouts and provide meaningful and clinically relevant results 
based on previous slice culture analyses and their connection with clinical response 
and outcome data. 
The marked cytostatic effects observed in ex-vivo cultured precision-cut tissue slices of 
human PDAC treated with selenium compounds highlight these as promising candidate drugs 
for the treatment of this still devastating disease. The results merit further investigations, 
including animal experiments and clinical trials. 
The intensively pursued therapeutic breakthrough that significantly curbs PDAC progression 
will benefit many patients, also opening the possibility of surgery for patients currently 
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